

## CURRICULUM VITAE

William V. Padula, Ph.D.

### PERSONAL DATA

#### Address and Contact

Department of Pharmaceutical and Health Economics  
USC Schaeffer Center  
635 Downey Way (VPD)  
Los Angeles, CA 90089

Mobile: 203-506-0161  
Office: 213-821-0552  
Fax: 213-740-3460  
E-mail: padula@usc.edu

**Date of Birth:** January 7, 1984

**Place of Birth:** New Haven, CT, USA

### EDUCATION AND TRAINING

- B.S. 2006 (Chemical Engineering) Northwestern University, Evanston, IL
- M.S. 2008 (Evaluative Clinical Science) Dartmouth College, Hanover, NH
- Ph.D. 2014 (Pharmaceutical Outcomes Research) University of Colorado, Aurora, CO
- M.Sc. 2015 (Analytics) The University of Chicago, Chicago, IL
- Postdoctoral Fellow 2015 (Health Economics) The University of Chicago, Chicago, IL

#### Doctoral Dissertation

“Comparative Effectiveness of Quality Improvement Interventions to Prevent Hospital-acquired Pressure Ulcers in U.S. Academic Medical Centers.”

**Committee:** R. Valuck (Advisor), K. Nair (Chair), J. Campbell, M.B. Makic, H. Wald, M. Mishra

### PROFESSIONAL EXPERIENCE

- 2018 – present Assistant Professor (Tenure-Track), Department of Pharmaceutical & Health Economics, School of Pharmacy, University of Southern California, Los Angeles, CA.
- 2018 – present Fellow, Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA.
- 2020 – present Scholar, Mentored Career Development in Clinical and Translational Science (MCD-CTS) Program, Southern California Clinical and Translational Science Institute (SC-CTSI), University of Southern California, Los Angeles, CA

#### Other Professional Appointments

- 2019 Visiting Fellow, Centre for Health Economics, University of York, York, UK
- 2018 – present Affiliate Faculty, The Armstrong Institute for Patient Safety & Quality, Johns Hopkins Medicine, Baltimore, MD.
- 2018 – present Adjunct Faculty, Department of Acute and Chronic Care, School of Nursing, The Johns Hopkins University, Baltimore, MD.

- 2018 – 2021 Honorary Appointment, University of Technology Sydney, Sydney, Australia
- 2018 – 2019 Visiting Fellow, Oxford Institute for Nursing, Midwifery and Allied Health Research (OxINMAHR), Oxford Brookes University, Oxford, UK
- 2015 – 2018 Assistant Professor (Tenure-Track), Department of Health Policy and Management, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, MD.
- 2017 – 2018 Assistant Professor (Joint), Division of General Internal Medicine, The Johns Hopkins Medicine, Baltimore, MD.
- 2016 – 2019 Assistant Professor (Joint), The Armstrong Institute for Patient Safety & Quality, Johns Hopkins Medicine, Baltimore, MD.
- 2016 – 2018 Assistant Professor (Joint), Department of Acute and Chronic Care, School of Nursing, The Johns Hopkins University, Baltimore, MD.
- 2016 – 2017 Visiting Scholar, Oxford Institute for Nursing, Midwifery and Allied Health Research (OxINMAHR), Oxford Brookes University, Oxford, UK

**Other Professional Experience**

- 2005 Summer Intern, Sensory Motor Performance Program, Rehabilitation Institute of Chicago (RIC), Chicago, IL.  
Researched biomechanical devices to improve quality of life for stroke survivors
- 2006 Summer Intern, Kymanox LLC, Highland Park, IL.  
Developed economic tool for improved manufacturing processes.
- 2006 – 2008 Project Engineer, Kymanox LLC, Highland Park, IL.  
Biochemical engineer to design and validate manufacturing equipment for biopharmaceutical clients.
- 2008 – 2013 Teaching Assistant, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO.  
Graded homework and exams for Pharm.D. courses in pharmaceutical sciences: Pharmacy Core Skills; Pediatric Pharmacy; Business Law and Ethics. Taught regular sessions, led discussion sections and developed exam questions for graduate courses in pharmaceutical sciences: Biostatistics and Epidemiology; Health Economics; U.S. Health Policy.
- 2009 – 2010 Research Assistant, Clinical-Translational Science Award (CTSA) Program, University of Colorado, Aurora, CO.  
Project Manager for principal investigator (A. Libby) of the University of Colorado CTSA program in medicine.
- 2010 Graduate Intern, Global Health Economics, Amgen Inc., Thousand Oaks, CA.  
Conducted Markov model of cost-effectiveness of dyspnea stabilization in acute heart failure patients for early-phase biologic.
- 2011 – 2013 Economic Modeler, Global Health Economics, Amgen Inc (Thousand Oaks, CA).  
Developed cost-effectiveness and budget impact models of early-phase and brand-name biologics, and performed secondary data analyses of MarketScan and proprietary datasets. Clinical areas: cardiology; nephrology; neurology; hematology/oncology.

2013 – 2015 Postdoctoral Fellow, Department of Medicine, University of Chicago, Chicago, IL.  
Two-year fellowship in health services research and concentration in health economics support by AHRQ T32/F32 National Research Service Award.  
**Sponsors:** David O. Meltzer and Robert D. Gibbons

2017 – present Principal, Monument Analytics, Baltimore, MD.

### **Certifications**

2006 Biotechnology & Biochemical Engineering Certificate, McCormick School of Engineering, Northwestern University, Evanston, IL

2006 Undergraduate Leadership Program (ULP) Certificate, School of Communication, Northwestern University, Evanston, IL

2008 Lean Six Sigma Certificate (Green Belt), Thayer School of Engineering, Dartmouth College, Hanover, NH

## **PROFESSIONAL ACTIVITIES**

### **Society Leadership**

2016 – 2019 Commissioner, American Nurses Credentialing Center (ANCC) Magnet® Recognition Program, Silver Spring, MD.

2017 – present Board of Directors, National Pressure Injury Advisory Panel (NPIAP), Washington, D.C.

2019 – 2020 Treasurer, NPIAP, Washington D.C.

2021 – 2022 President, NPIAP, Washington D.C.

2021 – present Board of Directors, The Wound Care Collaborative Community (WCCC)

2023 – present Immediate Past-President, NPIAP, Washington D.C.

### **Society Membership**

2009 – present Member, International Society of Pharmacoeconomics and Outcomes Research (ISPOR)

2009 – 2013 Founding Member and President (2010-11), ISPOR Colorado Student Chapter

2008 – present Member, Society of Medical Decision Making (SMDM)

2013 – present Member, AcademyHealth

2013 – present Member, Society of Hospital Medicine (SHM)

2015 – present Member, International Health Economics Association (iHEA)

2017 – present Member, American Statistical Association (ASA)

2018 – present Member, American Medical Informatics Association (AMIA)

2021 – present Member, American Society of Health Economists (ASHEcon)

### **Participation on Advisory Panels**

2016 – 2018 Member, Faculty Advisory Council, ISPOR.

- 2017 External Thought Leader, ANCC Strategic Planning Meeting, Silver Spring, MD.
- 2017 – present Member, Global Scientific Advisory Board, Molnlycke Health Care Inc., Atlanta, GA.
- 2020 Member, Scientific Advisory Board, Phoenix Tissue Repair, Boston, MA
- 2021 Member, Medical Advisory Board, Rehabtronics, Alberta, Canada
- 2021 Member, Medical Advisory Board, Regenesys Bio, Scottsdale, AZ
- 2022 – present Member, Advisory Board, Council for Affordable Health Coverage, Washington, DC

**Program and Project Development**

- 2013 – 2015 Member, Task Force on Simulation Modeling, ISPOR
- 2013 – 2015 Member, Chicago Learning and Effectiveness Advancement Research Network (LEARN)
- 2013 – 2015 Member, Steering Committee, Chicago-area Patient Centered Outcomes Research Network (CAPriCORN), a PCORI-funded clinical database research network
- 2014 – 2015 Advisor, ANCC Magnet Designated Centers of Excellence in Pressure Ulcer Prevention, Virginia Commonwealth University Pressure Ulcer Summit
- 2015 – 2016 Advisor, Diabetes Center of Excellence, American College of Physicians (ACP)
- 2015 – present Member, Task Force on Optimization Methods for Healthcare Delivery, ISPOR
- 2019 – present Member, Health Technology Assessment (HTA) Panel, USC Schaeffer Center and The Aspen Institute.
- 2019 – 2022 Co-Chair & Member, Task Force on Machine Learning Methods for Healthcare, ISPOR.
- 2020 – 2022 Member, Health Science Policy Advisory Council, ISPOR.
- 2021 Member, Steering Council, WCCC
- 2021 – 2023 Member, International Planning Committee, ISPOR
- 2022 – present Member, Special Task Force on Value-based Health Care, ISPOR

**Testimony**

- 2017 Maryland State Senate, Finance Committee, Subcommittee on Healthcare
  - Format: Working Group
  - Topic: SB 413 – Generic Anti-Price-Gouging
  - Chaired by: Sen. Feldman
  - Date: February 20, 2017
  
- 2017 Maryland State House of Delegates, Health and Government Operations Committee
  - Format: Committee Hearing
  - Topic: HB 631 – Generic Anti-Price-Gouging; HB 666 – Drug Price Transparency
  - Chaired by: Rep. Pendergrass
  - Date: February 23, 2017
  
- 2018 Maryland State Senate, Finance Committee, Subcommittee on Healthcare
  - Format: Committee Hearing
  - Topic: SB 1023 – Drug Price Review Commission
  - Chaired by: Sen. Middleton
  - Date: February 28, 2018

- 2018 Maryland State House of Delegates, Health and Government Operations Committee
- Format: Committee Hearing
  - Topic: HB 1194 – Drug Price Review Commission
  - Chaired by: Rep. Pendergrass
  - Date: March 6, 2018

## EDITORIAL ACTIVITIES

### Editorial Staff

2019 – present Associate Editor, *Value in Health*

### Editorial Boards

2017 – present *Wound Management & Prevention* (formerly *Ostomy Wound Management*)

2017 – present *Applied Health Economics and Health Policy*

2018 – 2021 *Journal of Clinical Nursing*

### Peer Reviewer Activities

*Annals of Internal Medicine*, 12 manuscripts

*Applied Health Economics & Health Policy*, 10 manuscripts

*British Medical Journal*, 1 manuscript

*BMJ Quality & Safety*, 4 manuscripts

*Clinical Risk*, 1 manuscript

*Drugs – Real World Outcomes*, 1 manuscript

*Health Affairs*, 2 manuscripts

*International Wound Journal*, 1 manuscript

*Journal of Interprofessional Education and Practice*, 1 manuscript

*Journal of Wound, Ostomy and Continence Nurses*, 3 manuscripts

*Journal of Nursing Management*, 3 manuscripts

*Medical Care*, 6 manuscripts

*New England Journal of Medicine*, 1 manuscript

*Ostomy Wound Management*, 4 manuscripts

*PharmacoEconomics*, 2 manuscripts

*Quality Management in Health Care*, 1 manuscript

*Vaccine*, 1 manuscript

*Value in Health*, 3 manuscripts

*Worldviews in Evidence-Based Nursing*, 1 manuscript

*LGBT Health*, 1 manuscript

## HONORS AND AWARDS

### Honors

2014	“Top Reviewer of 2013,” <i>Annals of Internal Medicine</i>
2014	Best Abstract, Health Services Research Category by a Fellow, Department of Medicine Research Day, University of Chicago, Chicago, IL
2015	“Top Reviewer of 2014,” <i>Annals of Internal Medicine</i>
2015	Best-in-Show, M.Sc. Analytics Thesis Defense, University of Chicago
2016	“Top Reviewer of 2015,” <i>Annals of Internal Medicine</i>
2017	“Top Reviewer of 2016,” <i>Annals of Internal Medicine</i>
2019	Stanley A. Klatsky, M.D., Business of Healthcare Lectureship, Johns Hopkins Medicine, Baltimore, MD
2020	“Top Article of 2019,” <i>BMJ Quality &amp; Safety</i>

### Awards

2005	Service Award, Segal Design Institute, Northwestern University, Evanston, IL.
2010	Travel Award, PharmaSUG Student Scholarship Program, Orlando, FL.
2011	Outstanding Poster Presentation Award, ISPOR Western Pharmacoeconomics Conference, Seattle, WA.
2012	Travel Award, ISPOR European Congress, Berlin, Germany.
2014	Diversity Small Grant Award (Spring), University of Chicago Medicine, Chicago, IL.
2014	Diversity Small Grant Award (Fall), University of Chicago Medicine, Chicago, IL.
2015	Outstanding Dissertation Award (Honorable Mention), AcademyHealth, Minneapolis, MN.
2016	Young Investigator Award, Society for Advancement in Wound Care (SAWC), Atlanta, GA.
2016	Research Award – Best New Investigator, ISPOR European Congress, Vienna, Austria.
2018	Faculty Award for Excellence in U.S. Public Health Practice, 2018, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
2019	Thomas Steward Founders Award for Excellence in Public Policy, National Pressure Ulcer Advisory Panel (NPUAP), St. Louis, MO.
2019	ISPOR 2019 Paper of the Year Award for HEOR Excellence in Application: “The Value of Hospital Resources for Effective Pressure Injury Prevention: A Cost-effectiveness Analysis.” ISPOR Annual Meeting, New Orleans, LA.
2021	Bernie J. O’Brien New Investigator Award of 2021, ISPOR
2022	Value Assessment Initiative Award, PhRMA Foundation
2023	Thomas Steward Founders Award for Excellence in Public Policy, National Pressure Injury Advisory Panel (NPIAP), San Diego, CA.
2023	Frontier Award, PhRMA Foundation

## PUBLICATIONS

\*Corresponding Author, †First or Senior Author, ‡Primary Mentor of Student or Fellow for Manuscript

### Journal Articles (Peer Reviewed)

1. Padula WV, Nelson CA, **Padula WV**, Benabib R, Yilmaz T, Krevisky S. Modifying postural adaptation following a CVA through prismatic shift of the visuo-spatial egocenter. *Brain Injury*, 2009 June; 23(6):566-576. PMID: 19484630
2. Cordero-Coma M, Yilmaz T, **Padula WV**, Rodriguez E, Lanier ST. Statistical Process Control Charts for Ophthalmology. *Graefes Archives of Clinical & Experimental Ophthalmology*, 2011;249(7):1103-5. PMID: 20824435
3. Yilmaz T, Cordero-Coma M, Lavaque AJ, Gallagher MJ, **Padula WV**. Triamcinolone and intraocular sustained-release delivery systems in diabetic retinopathy. *Current Pharmaceutical Biotechnology*, 2011; 12(3):337-46. PMID: 20939800
4. Sills MR, Hall M, Simon HK, Fieldston ES, Walter N, Levin JE, Brogan TV, Hain PD, Goodman DM, Fritch-Levens DD, Fagbuyi DB, Mundorff MB, Libby AM, Anderson HO, **Padula WV**, Shah SS. Resource burden at children's hospitals experiencing surge volumes during the spring 2009 H1N1 influenza pandemic. *Academic Emergency Medicine*, 2011;18(2):158-66. PMID: 21314775
5. **Padula WV**\*†, Mishra MK, Makic MB, Sullivan PW. Improving the Quality of Pressure Ulcer Care with Prevention: a cost-effectiveness analysis. *Medical Care*, 2011;49(4):385-92. PMID: 21368685
6. Cantu RV, Bell JE, **Padula WV**, Nahikian KR, Pober DM. How Do Emergency Room Physicians in Two Rural States Rate their Orthopaedic On-call Coverage? *Journal of Orthopaedic Trauma*, 2012 Jan;26(1):54-8. PMID: 21904223
7. **Padula WV**\*†, Mishra MK, Weaver CD, Yilmaz T, Splaine ME. Building information for systematic improvement of the prevention of hospital-acquired pressure ulcers with statistical process control charts and regression. *BMJ Quality & Safety*, 2012 Jun;21(6):473-80. PMID: 22447820.
8. Grover R, **Padula WV**†, Van Vliet M, Ridgway EB. Comparing Five Alternative Methods of Breast Reconstruction Surgery: A Cost-Effectiveness Analysis. *Plastic & Reconstructive Surgery*, 2013 Nov;132(5):709-723. PMID: 24165623
9. **Padula WV**\*†, Allen RR, Nair KV. Determining the Cost of Obesity and its Common Comorbidities from a Commercial Claims Database. *Clinical Obesity*, 2014 Feb;4(1):53-58. PMID: 25425133
10. **Padula WV**\*†, Mishra MK, Makic MB, Valuck RJ. A Framework of Quality Improvement Interventions to Implement Evidence-Based Practices for Pressure Ulcer Prevention. *Advances in Skin & Wound Care*, 2014 Jun;27(6):280-4. PMID: 24836619
11. **Padula WV**\*†, Duffy MP, Yilmaz T, Mishra MK. Integrating Systems Engineering Practice with Health-care Delivery. *Health Systems*, 2014 Nov;3(3):159-64.
12. **Padula WV**\*†, Cordero-Coma M, Yilmaz T, Padula WV, Ghallager MJ, Campbell JD. Comparing Prednisone and Methotrexate to Off-Label Biologic Infliximab for Management of Ocular Uveitis: a cost-minimization analysis. *Journal of Health Economics and Outcomes Research*, 2015;2(2):131-46.
13. Marshall DA, Burgos-Liz L, IJerman MJ, Osgood ND, **Padula WV**, Higashi MK, et al. Applying Dynamic Simulation Modeling Methods in Health Care Delivery Research – The SIMULATE Checklist: Report of the ISPOR Simulation Modeling Emerging Good Practices Task Force. *Value in Health*, 2015 Jan;18(1):5-16. PMID: 25595229

14. Marshall DA, Burgos-Liz L, IJzerman MJ, Osgood ND, **Padula WV**, Higashi MK, et al. Selecting a Dynamic Simulation Modeling Method for Health Care Delivery Research – Part 2: Report of the ISPOR Simulation Modeling Emerging Good Practices Task Force. *Value in Health*, 2015 Mar;18(2):5-16. PMID: 25595229
15. Conti RM, **Padula WV**, Larson RA. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the US and the EU. *Annals of Hematology*, 2015 Apr;94(suppl 2):249-57. PMID: 25814091
16. **Padula WV**<sup>†</sup>, Valuck RJ, Makic MB, Wald HL. Factors Influencing Adoption of Hospital-acquired Pressure Ulcer Prevention Programs in U.S. Academic Medical Centers. *Journal of Wound, Ostomy and Continence Nursing*, 2015 Jul-Aug;42(4):327-30. PMID: 25933124
17. **Padula WV**<sup>†</sup>, Makic MB, Mishra MK, Campbell JD, Nair KV, Wald HL, Valuck RJ. Comparative effectiveness of quality improvement interventions for pressure ulcer prevention in academic medical centers in the United States. *Joint Commission Journal of Quality and Patient Safety*, 2015;41(6):246-56. PMID: 25990890
18. **Padula WV**<sup>†</sup>, Makic MBF, Wald HL, Campbell JD, Nair KV, Mishra MK, Valuck RJ. Hospital-acquired Pressure Ulcers at Academic Medical Centers in the United States, 2008--2012: Tracking Changes Since the CMS Nonpayment Policy. *Joint Commission Journal of Quality and Patient Safety*, 2015;41(6):257-63. PMID: 25990891
19. Wray CM, Flores A, **Padula WV**, Prochaska MT, Meltzer DO, Arora VM. Measuring patient experiences on hospitalist and teaching services: Patient Responses to a 30-day postdischarge questionnaire. *Journal of Hospital Medicine*, 2016 Feb;11(2):99-104. PMID: 26381606
20. **Padula WV**<sup>†</sup>, Mishra MK, Makic MBF, Wald HL, Campbell JD, Nair KV, Valuck RJ. Increased Adoption of Quality Improvement Interventions to Implement Evidence-Based Practices for Pressure Ulcer Prevention in U.S. Academic Medical Centers. *Worldviews in Evidence Based Nursing*, 2015;12(6):328-336. PMID: 26462012
21. Marshall DA, Burgos-Liz L, Pasupathy KS, **Padula WV**, IJzerman MJ, Wong PK, Higashi MK, Engbers J, Wiebe S, Crown W, Osgood ND. Transforming Health Care Delivery: Integrating Dynamic Simulation Modeling and Big Data in Health Economics and Outcomes Research. *PharmacoEconomics*, 2015 Oct 26. PMID: 26497003
22. **Padula WV**<sup>†</sup>, Heru S, Campbell JD. Societal and policy implications of provider coverage for primary and preventive care in the U.S. transgender population: a cost-effectiveness analysis. *Journal of General Internal Medicine (JGIM)*, 2016 Apr;31(4):394-401. PMID: 26481647
23. Padula WV, Subramanian P, Spurling A, Jenness J, **Padula WV**<sup>†</sup>. Risk of fall (RoF) intervention by affecting visual egocenter through gait analysis and yoked prisms. *NeuroRehabilitation*, 2015 Oct 20;37(2):305-14. PMID: 26484522
24. **Padula WV**<sup>†</sup>, Blackshaw L, Brindle CT, Volchenbourn SL. An Approach to Acquiring, Normalizing and Managing EHR Data from a Clinical Data Repository for Studying Pressure Ulcer Outcomes. *Journal of Wound, Ostomy and Continence Nursing*, 2016 Jan-Feb;43(1):39-45. PMID: 26727681
25. Creehan SA, Cuddigan J, Gonzalez D, Nix D, **Padula WV**, Pittman J, Pontieri-Lewis V, Walden C, Wells B, Wheeler R. Developing Centers of Pressure Ulcer Prevention Excellence: A Framework for Sustainability. *Journal of Wound, Ostomy and Continence Nursing*, 2016 Mar-Apr;43(2):121-8. PMID: 26808304
26. **Padula WV**<sup>†</sup>, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM. Cost-effectiveness of Tyrosine Kinase Inhibitors Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After U.S. Generic Entry of Imatinib. *Journal of the National Cancer Institute (JNCI)*, 2016 Mar 4;108(7). PMID: 26944912.



27. **Padula WV\***<sup>†</sup>, Gibbons RD, Valuck RJ, Makic MBF, Mishra MK, Pronovost PJ, Meltzer DO. Are Evidence-based Practices Associated with Effective Prevention of Hospital-acquired Pressure Ulcers in U.S. Academic Medical Centers? *Medical Care*, 2016 May;54(5):512-8. PMID: 27078824
28. Walia G, Wong AL, Lo AY, Mackert GA, Carl HM, Pedreira RA, Bello R, Acquino CS, **Padula WV\***<sup>‡</sup>, Sacks J. Efficacy of Monitoring Devices in Support of Prevention of Pressure Injuries: Systematic Review and Meta-Analysis. *Advances in Skin & Wound Care*, 2016 Dec;29(12):567-574. PMID: 27846030
29. **Padula WV\***<sup>‡</sup>, Millis MA, Worku A, Pronovost PJ, Bridges JFP, Meltzer DO. Individualized Cost-effectiveness Analysis of Patient-centered Care: a case series of hospitalized patient preferences departing from practice-based guidelines. *Journal of Medical Economics*, 2017 Mar;20(3):288-96. PMID: 27786569
30. Crown W, Buyukkaramikli N, Thokala P, Morton A, Sir MY, Marshall DA, Tosh J, **Padula WV**, Ijzerman MJ, Wong PK, Pasupathy KS. Constrained Optimization Methods in Health Services Research-An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. *Value in Health*, 2017 Mar;20(3):310-319. PMID: 28292475
31. **Padula WV\***<sup>†</sup>, Makic MBF. View From Here: Informal Leadership Translating Evidence-Based Practices for Pressure Ulcer Prevention in the Hospital Setting. *Journal of Wound, Ostomy and Continence Nursing*, 2017 Mar/Apr;44(2):153-154. PMID: 28060030
32. **Padula WV\***<sup>‡</sup>, Gibbons RD, Pronovost PJ, Hedeker D, Mishra MK, Makic MBF, Bridges JFP, Wald HL, Valuck RJ, Ginensky AJ, Ursitti A, Venable LR, Epstein Z, Meltzer DO. Using Clinical Data to Predict High-cost, Performance Coding Issues Associated with Pressure Ulcers: a multilevel cohort model. *Journal of the American Medical Informatics Association (JAMIA)*, 2017 Apr;24(e1):e95-e102. PMID: 27539199
33. Padula WV, Capo-Aponte JE, **Padula WV**, Singman EL, Jenness J. The consequence of spatial visual processing dysfunction caused by traumatic brain injury (TBI). *Brain Injury*, 2017;31(5):589-600. PMID: 28440687
34. **Padula WV\***<sup>‡</sup>, Baker K. Coverage for Gender-Affirming Care: Making Health Insurance Work for Transgender Americans. *LGBT Health*, 2017 Aug;4(4). PMID:28708447.
35. Hong JC, Blankstein R, Shaw LJ, **Padula WV\***<sup>‡</sup>, Arrieta A, Fialkow JA, Blumenthal RS, Blaha MJ, Krumholz HM, Nasir K. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines: A Cost-effectiveness Analysis. *JACC Cardiovasc Imaging*, 2017 Aug; 10(8):938-52. PMID: 28797417.
36. Moran D, Shrimel MG, Nang S, Vycheth I, Vuthy D, Hong R, **Padula WV\***<sup>‡</sup>, Park KB. Cost-effectiveness of Craniotomy for Epidural Hematomas at a Major Government Hospital in Cambodia. *World Journal of Surgery*, 2017 Sep;41(9):2215-2223. PMID: 28444463
37. **Padula WV\***<sup>†</sup>. Effectiveness and Value of Prophylactic Five-Layer Foam Sacral Dressings to Prevent Hospital-Acquired Pressure Injuries in Acute Care Hospitals: an Observational Cohort Study. *Journal of Wound, Ostomy & Continence Nursing*, 2017 Sep/Oct;44(5):413-19. PMID: 28816929.
38. Offodile AC, Shekter CC, Tucker A, Watzker A, Ottino K, Zammert M, **Padula WV\***<sup>‡</sup>. Preoperative paravertebral blocks for the management of acute pain following mastectomy: a cost-effectiveness analysis. *Breast Cancer Research and Treatment*, 2017 Oct;165(3):477-484. PMID: 28677010

39. **Padula WV\***, McQueen RB, Pronovost PJ. Can Economic Model Transparency Improve Provider Interpretation of Cost-effectiveness Analysis? Evaluating Tradeoffs Presented by the Second Panel on Cost-effectiveness in Health and Medicine. *Medical Care*, 2017 Nov;55(11):915-17. PMID: 29028753
40. **Padula WV\***, McQueen RB, Pronovost PJ. Finding Resolution for the Responsible Transparency of Economic Models in Health and Medicine. *Medical Care*, 2017 Nov;55(11):909-11. PMID: 29028755
41. **Padula WV\***, Phelps CE, Moran D, Earley C. Allocating Provider Resources to Diagnose and Treat Restless Leg Syndrome: A Cost-Utility Analysis. *Sleep Medicine*, 2017 Oct;38:44-49. PMID: 29031755.
42. **Padula WV\***, Connor KA, Mueller JM, Hong JC, Velazquez GC, Johnson SB. Cost-benefit of Comprehensive Primary and Preventive School-based Health Care. *American Journal of Preventive Medicine*, 2018 Jan;54(1):80-86. PMID: 29031700.
43. Parasrampur S, Oakes AH, Wu SS, Parikh MA, **Padula WV\***. Value and Performance of Accountable Care Organizations: A Cost-Minimization Analysis. *International Journal of Technology Assessment in Health Care*, 2018 Jan;34(4):388-392. PMID: 29991357.
44. Hong JC, Saraswat MK, Ellison TA, Magruder JT, Gardner JM, **Padula WV\***, Whitman GJR. *Staphylococcus aureus* Prevention Strategies in Cardiac Surgery: A Cost-effectiveness Analysis. *Annals of Thoracic Surgery*, 2018 Jan;105(1):47-53. PMID 28987394.
45. Hoyer E, **Padula WV\***, Brotman D, Reid N, Leung C, Lepley D, Deutschendorf A. Patterns of Hospital Performance on the Hospital-Wide 30-Day Readmission Metric: Is the Playing Field Level? *Journal of General Internal Medicine (JGIM)*, 2018 Jan;33(1):57-64. PMID: 28971369.
46. Hong JC, **Padula WV\***, Hollin IL, Hussain T, Dietz KB, Halbert JP, Marsteller JA, Cooper LA. Care Management to Reduce Disparities and Control Hypertension in Primary Care. *Medical Care*, 2018 Feb;56(2):179-185. PMID: 29239999.
47. **Padula WV\***, Davidson PM, Jackson D, Pedriera R, Pronovost PJ. Unintended Consequences of Quality Improvement Programs on the Prevention of Hospital-acquired Conditions. *J Patient Safety & Risk Management*, 2018 Jun;23(3):123-127.
48. Gonzales E, Lee Y, **Padula WV**, Jung LS. Exploring the Consequences of Discrimination and Health for Retirement by Race and Ethnicity: Results from the Health and Retirement Study. *Social Science Research Network*, 2018 Sep; CRR-WP 2018-6.
49. Crown W, Buyukkaramikli N, Sir MY, Thokala P, Morton A, Marshall DA, Tosh JC, Ijzerman MJ, **Padula WV**, Pasupathy KS. Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force. *Value in Health*, 2018 Sep; 21(9):1019-1028. PMID: 30224103.
50. Heyward J, **Padula WV**, Tierce J, Alexander C. The Value of U.S. Pharmacopeial Standards: A Review of the Literature. *J Pharmaceutical Sciences*, 2018;107(10):2611-2617. PMID: 29908148.
51. Zhou M, Oakes AH, Bridges JFP, **Padula WV\***, Segal JB. Regional Supply of Medical Resources and Systemic Overuse of Health Care Among Medicare Beneficiaries. *Journal of General Internal Medicine (JGIM)*, 2018 Dec;33(12):2127-2131. PMID: 30229364.
52. **Padula WV\***, Ballreich J, Anderson GF. Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry. *Applied Health Economics & Health Policy*, 2018 Dec;16(6):753-763. PMID: 30058011

53. **Padula WV\***, Pronovost PJ, Makic MB, Wald HL, Moran D, Mishra MK, Meltzer DO. The Value of Hospital Resources for Effective Pressure Injury Prevention: A Cost-effectiveness Analysis. *BMJ Quality & Safety*, 2019 Feb;28(2):132-141. PMID: 30097490.
54. Voong KR, Liang OS, Dugan P, Torto D, **Padula WV\***, Senter JP, Lang M, Hooker CM, Feliciano J, Broderick S, Yarmus L, Khanna K, Narang A, Hales RK. Thoracic Oncology Multidisciplinary Clinic Reduces Unnecessary Health Care Expenditure Used in the Workup of Patients with Non-small-cell Lung Cancer. *Clinical Lung Cancer*, 2019 Jul;20(4):e430-e441. PMID: 30956040
55. Yin LX, **Padula WV\***, Gadkaree S, Motz K, Rahman S, Predmore Z, Gelbard A, Hillel AT. Health Care Costs and Cost-effectiveness in Laryngotracheal Stenosis. *Otolaryngology Head and Neck Surgery*, 2019 Apr;160(4):679-686. PMID: 30481123.
56. Spaulding EM, Marvel FA, Lee MA, Yang WE, Demo R, Wang J, Xun H, Shah L, Weng D, Fashanu OE, Carter J, Sheidy J, McLin R, Flowers J, Majmudar M, Elgin E, Vilarino V, Lumelsky D, Bhardwaj V, **Padula WV\***, Allen JK, Martin SS. Corrie Health Digital Platform for Self-Management in Secondary Prevention After Acute Myocardial Infarction. *Circulation: Cardiovascular Quality & Outcomes*, 2019 May;12(5):e005509. PMID: 31043065.
57. Sohrt A, Maerkedahl A, **Padula WV\***. Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Resuable EEG Cup Electrodes. *Pharmacoeconomics Open*, 2019 Jun;3(2):275. PMID: 30151817.
58. **Padula WV\***, Delarmente B. The National Cost of Hospital-Acquired Pressure Injuries in the United States. *International Wound Journal*, 2019 Jun;16(3):634-640. PMID: 30693644.
59. Ishigami J, **Padula WV\***, Grams ME, Chang AR, Jaar B, Gansevoort RT, Bridges JFP, Kovesdy CP, Uchida S, Coresh J, Matsushita K. Cost-effectiveness of Pneumococcal Vaccination Among Patients with CKD in the United States. *American Journal of Kidney Disease*, 2019 Jul;74(1):23-25. PMID: 30898360.
60. Jackson D, Hutchinson M, Neville S, **Padula WV**, Usher K, Gardner S, Betteridge R, Durrant L. Characteristics of people with pressure ulcers using one year's routinely collected data in a defined diverse community. *Journal of Wound Care*, 2019 Sep 2;28(9):576-584. PMID: 31513500.
61. **Padula WV\***, Chen YH, Santamaria N. Five-layer border dressings as part of a quality improvement bundle to prevent pressure injuries in US skilled nursing facilities and Australian nursing homes: a cost-effectiveness analysis. *International Wound Journal*, 2019 Dec;16(6):1263-1272. PMID: 3147534.
62. Banerjee T, Malaviya S, Alfonso YN, Wedlock P, Pariyo G, Pasha O, Constenla D, Brenzel L, Edoka I, Hofman K, Kinghorn A, Mayora C, Chatterjee S, Sodani PR, Zaldi S, Huda M, Abrejo F, **Padula WV\***, Bishai D. Immunization Decision-Making Capacity Building in Low- and Middle-Income Countries Through Teaching Vaccine Economics Everywhere: a program evaluation. *Journal of Global Health Science*, 2019 Dec;1(2):e48.
63. Trujillo AJ, Karmarkar T, Alexander GC, **Padula WV\***, Greene JA, Anderson GF. Fairness in drug prices: do economists think differently from the public? *Health Economics, Policy and Law*, 2020 Jan;15(1):18-29. PMID: 30509337.
64. Azad NS, Leeds IL, Wanjau W, Shin EJ, **Padula WV\***. Cost-utility of colorectal cancer screening at 40 years old for average-risk patients. *Preventive Medicine*, 2020 Jan;133:106003. PMID: 32001308.
65. Yilmaz T, Gallagher MJ, Cordero-Coma M, Gealy D, Loporchio S, **Padula WV**, Loporchio D, Statler B, Migliori M. Discontinuation and nonpublication of interventional clinical trials conducted in ophthalmology. *Canadian Journal of Ophthalmology*, 2020 Feb;55(1):71-75. PMID: 31712042.

66. **Padula WV<sup>\*†</sup>**, [Malaviya S](#), [Hu E](#), Creehan S, Delmore B, Tierce J. The cost-effectiveness of sub-epidermal moisture (SEM) scanning to assess pressure injury risk in U.S. health systems. *Journal of Patient Safety & Risk Management*, 2020 Mar;25(4):147-155.
67. [Shores D](#), [Mogul D](#), [Delarmente B](#), [Allen J](#), **Padula WV<sup>\*†</sup>**. Cost-effectiveness Analysis of Feeding Guidelines for Infants Following Intestinal Surgery. *Journal of Pediatric Gastroenterology & Nutrition*, 2020 May;70(5):657-663. PMID: 31977952.
68. **Padula WV<sup>\*†</sup>**, Black JM, Davidson PM, Kang SY, Pronovost PJ. Adverse Effects of the Medicare PSI-90 Hospital Penalty System on Revenue-Neutral Hospital-acquired Conditions. *Journal of Patient Safety*, 2020 Jun;16(2):e97-e102. PMID: 30110019.
69. [Karmarkar T](#), [Trujillo A](#), **Padula WV<sup>\*†</sup>**, Greene J, Anderson GF. Fairness in the trade-off between drug price regulation and investment in research and development: a survey of economists. *Journal of Behavior Economics and Policy*, 2020;4(1):49-55.
70. El Genedy M, Hahnel E, Tomova-Simitchieva T, **Padula WV**, Hauss A, Lober N, Blume-Peytavi U, Kottner J. Cost-effectiveness of multi-layered silicone foam dressings for prevention of sacral and heel pressure ulcers in high-risk intensive care unit patients: An economic analysis of a randomized controlled trial. *International Wound Journal*, 2020 Oct;17(5):1291-1299. PMID: 32391627
71. MacDonnell-Yilmaz R, [Anderson K](#), DeNardo B, Sprinz P, **Padula WV<sup>\*†</sup>**. Cost-effectiveness Analysis of Screening Extremely Low Birthweight Children for Hepatoblastoma Using Serum Alpha-fetoprotein. *Journal of Pediatrics*, 2020 Oct;225:80-89. PMID: 32470475.
72. **Padula WV<sup>\*†</sup>**, [Parasrampur S](#), Socal M, Conti RM, Anderson GF. Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and the Associated Budget Impact in the U.S. *PharmacoEconomics*, 2020 Oct;38(10):1115-1121. PMID: 32533523.
73. [Meng D](#), Xu G, He L, Zhang M, **Padula WV<sup>\*†</sup>**, Davidson PM. Nursing Student's Perceived Value of the Work Environment: A Discrete Choice Experiment. *Geriatric Nursing*, 2020 Dec;42(1):94-98. PMID: 33164137.
74. [Moran D](#), Wu AW, Connors C, Chappidi MR, Sreedhara SK, Selter JH, **Padula WV<sup>\*†</sup>**. Cost-benefit analysis of a Support Program for Nursing Staff. *Journal of Patient Safety*, 2020 Dec;16(4):e250-e254. PMID: 28452914.
75. **Padula WV<sup>\*†</sup>**, Sculpher MJ. Ideas About Resourcing Health Care in the United States: Can Economic Evaluation Achieve Meaningful Use? *Annals of Internal Medicine*, 2021 Jan;174(1):80-85. PMID: 32986487.
76. [Karmarkar T](#), **Padula WV<sup>\*†</sup>**, Gaskin D, Watson EX, Rodriguez C. Characteristics Associated with Time-to-Treatment Initiation for Chronic Hepatitis C with New Direct Acting Antivirals. *Pharmacoepidemiology and Drug Safety*, 2021 Jan;30(1):86-96. PMID: 33090666.
77. **Padula WV<sup>\*†</sup>**, Davidson PM, [Nagarajan M](#), Pronovost PJ. Investing in Skilled Specialists to Grow Hospital Infrastructure for Quality Improvement. *Journal of Patient Safety*, 2021 Jan;17(1):51-55. PMID: 31343454.
78. **Padula WV<sup>\*†</sup>**, Cuddigan J, Ruotsi L, Black JM, Brienza D, Capasso V, Cox J, Delmore B, Holden-Mount S, Munoz N, Nie AM, Pittman J, Sonenblum S, Tescher A; for the National Pressure Injury Advisory Panel. Best-practices for Preventing Skin Injury Beneath Personal Protective Equipment During the COVID-19 Pandemic: A Position Paper from the National Pressure Injury Advisory Panel (NPIAP). *Journal of Clinical Nursing*, 2021 Feb;10.1111/jocn.15682. PMID:33534939.

79. **Padula WV**<sup>\*,‡</sup>, Chen HH, Phelps CE. Is the Choice of Cost-effectiveness Threshold in Cost-utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review. *Applied Health Economics & Health Policy*, 2021 March;19(2):155-162. PMID: 32812212
80. **Padula WV**<sup>\*,‡</sup>, Levin JS, Lee J, Anderson GF. Cost-effectiveness of total state coverage for hepatitis C medications. *American Journal of Managed Care*, 2021 May;27(5):e171-e177. PMID: 34002969
81. Xuan S, Colayco D, Hashimoto J, Barca J, Dekivadia D, **Padula WV**<sup>\*,‡</sup>, McCombs J. Impact of adding pharmacists and comprehensive medication management to a medical group's transition of care services. *Medical Care*, 2021 June;59(6):519-527. PMID: 33734196.
82. Conti RM, **Padula WV**, Becker RV, Salamone S. The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia. *J Manag Care Spec Pharm*. 2021 Aug;27(8):1077-1085. PMID: 34337991.
83. Sherry MK, Bishai DM, **Padula WV**<sup>\*,‡</sup>, Weiner JP, Szanton SL, Wolff JL. Impact of Neighborhood Social and Environmental Resources on Medicaid Spending. *American Journal of Preventive Medicine*, 2021 Aug;61(2):e93-e101. PMID: 34039496.
84. Marvel FA, Spaulding EM, Lee MA, Yang WE, Demo R, Ding J, Wang J, Xun H, Shah LM, Weng D, Carter J, Majmudar M, Elgin E, Sheidy J, McLin R, Flowers J, Vilarino V, Lumelsky DN, Bhardwaj V, **Padula WV**<sup>\*,‡</sup>, Shan R, Huynh PP, Wongvibulsin S, Leung C, Allen JK, Martin SS. Digital Health Intervention in Acute Myocardial Infarction. *Circulation: Cardiovascular Quality & Outcomes*, 2021 Jul;14(7):e007741. PMID: 34261332.
85. Davidson PM, Lin CJ, Beaman A, Jackson D, Reynolds NR, **Padula WV**<sup>\*,‡</sup>. Global digital social learning as a strategy to promote engagement in the era of COVID-19. *Journal of Clinical Nursing*, 2021 Aug;30(15-16):2366-2372. PMID: 33904196; PMCID: PMC8242900.
86. **Padula WV**<sup>\*,†</sup>, Lee KHC, Pronovost PJ. Using Economic Evaluation to Illustrate Value of Care for Improving Patient Safety & Quality: Choosing the Right Method. *Journal of Patient Safety*, 2021 Sep;17(6):e568-e574. PMID: 28786836
87. Bhardwaj V, Spaulding EM, Marvel FA, LaFave S, Yu J, Mota D, Lorigiano TJ, Huynh PP, Shan R, Yesantharao PS, Lee MA, Yang WE, Demo R, Ding J, Wang J, Xun H, Shah L, Weng D, Wongvibulsin S, Carter J, Sheidy J, McLin R, Flowers J, Majmudar M, Elgin E, Vilarino V, Lumelsky D, Leung C, Allen JK, Martin SS, **Padula WV**<sup>\*,‡</sup>. Cost-effectiveness of a Digital Health Intervention for Acute Myocardial Infarction Recovery. *Medical Care*, 2021 Nov;59(11):1023-1030. PMID: 34534188.
88. Seu, Bhat D, Wong A, Wong M, Nojoomi M, **Padula WV**<sup>\*,‡</sup>, Sacks JM. The Effect of Padded Adhesive Dressings and Body Position on Sacral Interface Pressure. *Journal of Patient Safety*, 2021 Dec;17(8):e1851-e1854. PMID: 32569097.
89. **Padula WV**<sup>\*,†</sup>, Malaviya S, Reid NM, Cohen BG, Chingcuanco F, Ballreich J, Tierce J, Alexander GC. Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis. *Journal of Medical Economics*, 2021 Jan-Dec;24(1):1060-1069. PMID: 34357843.
90. Tankumpuan T, Sindhu S, Perrin N, Commodore-Mensah Y, Budhathoki C, **Padula WV**<sup>\*,‡</sup>, Himmelfarb CD, Davidson PM. A Multi-Site Thailand Heart Failure Snapshot Study. *Heart Lung Circ*, 2022 Jan;31(1):85-94. PMID: 34364801.
91. **Padula WV**<sup>\*,†</sup>, Armstrong DG, Goldman DP. Complexity Bias in the Prevention of Iatrogenic Injury: Why Specific Harms May Inhibit Performance. *Mayo Clinic Proceedings*, 2022 Feb;97(2):221-224. PMID: 35120691

92. Kang SY, Yehia F, DeStefano M, Koszalka M, **Padula WV\***. The cost-effectiveness of beds with continuous lateral rotation therapy (CLRT) to prevent ventilator-associated pneumonia and hospital-acquired pressure injuries. *Journal of Patient Safety*, 2022 Mar;17(2):149-155. PMID: 30898360.
93. Tettelbach WH, Armstrong DG, Chang TJ, Jong JL, Glat PM, Hsu JH, Kelso MR, Niezgodna JA, Labovitz JM, Hubbs B, Forsyth RA, Cohen BG, Reid NM, **Padula WV\***. Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment. *J Wound Care*, 2022 Feb;31(suppl 2):S10-S31. PMID: 35148642
94. Karmarkar T, Rodriguez-Watson CV, Watson E, Zheng H, Gaskin DJ, **Padula WV\***. Value of Triage Treatment Strategies to Distribute Hepatitis C Direct-Acting Antiviral Agents in an Integrated Healthcare System: A Cost-Effectiveness Analysis. *Value in Health*, 2022 Apr:S1098-3015(22)00145-0. PMID: 35484030.
95. **Padula WV\***, Miano MA, Kelley MA, Crawford SA, Choy BH, Hughes RM, Gross R, Pronovost PJ. A Cost-Utility Analysis of Remote Pulse-Oximetry Monitoring of Patients with COVID-19. *Value in Health*, 2022 Jun;25(6):890-896. PMID:35667779.
96. **Padula WV\***, Kreif N, Vanness DJ, Adamson B, Rueda JD, Felizzi F, Jonsson P, IJzerman MJ, Butte A, Crown W. Machine Learning Methods in Health Economics and Outcomes Research – The PALISADE Checklist: A Report of the ISPOR Machine Learning Emerging Good Practices Task Force. *Value in Health*, 2022 Jul;25(7):1063-1080. PMID: 35779937.
97. Bhattacharyya S, Hariprasad SM, Albin TA, Dutta SK, John D, **Padula WV**, Harrison D, Joseph G. Suprachoroidal Injection of Triamcinolone Acetonide Injectable Suspension for Treatment of Macular Edema Associated with Uveitis in the United States: A Cost-effectiveness Analysis. *Value Health*, 2022 Oct;25(10):1705-1716. PMID: 36055922.
98. Choe JH, Abdel-Azim H, **Padula WV\***, Abou-el-Enein M. Cost-Effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-Line or Later Therapy in Replased or Refractory Diffuse Large B-Cell Lymphoma. *JAMA Network Open*, 2022 Dec;5(12):e2245956. PMID: 36520440.
99. Dietz DW, **Padula WV\***, Zheng H, Monson JRT, Pronovost PJ. Improving Value in Surgery: Opportunities in Rectal Cancer Care. A Surgical Perspective. *Annals of Surgery*. 2022 Nov 4. Epub ahead of print. PMID: 36538646.
100. Zheng H, Magee GA, Tan TW, Armstrong DG, **Padula WV\***. Cost-Effectiveness of Compression Therapy with Early Endovenous Ablation in Venous Ulceration for a Medicare Population. *JAMA Network Open*, 2022 Dec;5(12):e2248152. PMID: 36692566.
101. Cohen BG, Chingcuanco F, Zhang J, Reid NM, Lee V, Hong J, Deliargyris EN, **Padula WV\***. Cost-Effectiveness and Budget Impact of a Novel Antithrombotic Drug Removal System to Reduce Bleeding Risk in Patients on Preoperative Ticagrelor Undergoing Cardiac Surgery. *Am J Cardiovasc Drugs*. 2023 May. Epub ahead of print. PMID: 37204675.
102. Kapp S, Gertz M, Gefen A, **Padula W**, Alves P, Trevellini C, Ghosh A, Shea A, Cross A, Sousa I, Santamaria N. Clinical and cost effectiveness of a system for turning and positioning intensive care unit patients, when compared to usual care turning and positioning devices, for the prevention of hospital-acquired pressure injuries. A randomised controlled trial. *International Wound Journal*. 2023 Nov;20(9):3567-3579. PMID: 37295778.
103. Kapp S, Gertz M, Miller C, Gefen A, **Padula W**, Wilson L, Woodward M, Santamaria N. The clinical and cost effectiveness of remote expert wound nurse consultation for healing of pressure injuries among residential aged care patients: A protocol for a prospective pilot parallel cluster randomised controlled trial. *International Wound Journal*. 2023 Oct;20(8):2953-2963. PMID: 37529854.

104. Yu T, Padula WV<sup>\*†</sup>, Yieh L, Gong CL. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6/7 weeks' gestation in the United States. *Pediatric Neonatology*. 2023 Sep 11:S1875-9572(23)00146-8. PMID: 37758594.
105. Padula WV<sup>\*†</sup>, Crawford S, Kennerly S, Yap T. Estimating the Value of Repositioning Timing to Streamline Pressure Injury Prevention Efforts in Nursing Homes: A Cost-Effectiveness Analysis of the "TEAM-UP" Clinical Trial. *International Wound Journal*, 2023 (In Press).

#### Articles, Editorials and Letters (Not Peer Reviewed)

1. Padula WV<sup>\*†</sup>, Sullivan PW. Beyond Migraines: How Healthy Are The 2012 Presidential Candidates? *The Atlantic*, August 3, 2011.
2. Padula WV<sup>\*†</sup>, Mishra MK, Makic MB, Sullivan PW. In Reply: Improving the Quality of Pressure Ulcer Care with Prevention: a cost-effectiveness analysis. *Medical Care*, 2012 Feb;50(2):188-90. PMID: 22249924
3. Padula WV<sup>\*†</sup>, Breteler MJM. Sharing Perspectives on HTA from Both Sides of the Pond. *ISPOR Connections: A Journal of the International Society of Pharmacoeconomics and Outcomes Research*, 2013 Jan/Feb;19(1):15.
4. Padula WV<sup>\*†</sup>, Wald HM, Makic MBF. Pressure Ulcer Risk Assessment and Prevention. *Annals of Internal Medicine*, 2013 Nov;159(1):28-38 PMID: 23817702
5. Padula WV<sup>\*†</sup>, Padula WV. Is it worth the effort to create a learning healthcare delivery system? *Journal of Interprofessional Education & Practice*, 2015 Mar;1(1):8-9.
6. Padula WV<sup>\*†</sup>, IJzerman MJ, Crown W, Marshall DA. Dynamic Simulation Modeling to Evaluate Complex System Interventions for Health Care Delivery Research – What Methods for What Problems? *Value and Outcomes Spotlight: A Journal of the International Society of Pharmacoeconomics and Outcomes Research*, 2015 May/June;21(3).
7. Padula WV<sup>\*†</sup>, Wald HL, Meltzer DO. Pressure Ulcer Prevention and Management. *Annals of Internal Medicine*, 2015 Jul 21;163(2):148-9. PMID: 26192569
8. Padula WV<sup>\*†</sup>, Brindle CT, Makic MBF. Pressure Ulcer Treatment and Care. *Annals of Internal Medicine*, 2015 Oct 20;163(8):645. PMID: 26502122
9. Green JA and Padula WV. Targeting Unconscionable Prescription-Drug Prices – Maryland's Anti-Price-Gouging Law. *New England Journal of Medicine*, 2017 Jul 13;377(2):101-103. PMID: 28591520.
10. Padula WV<sup>\*†</sup>, Pronovost PJ. Addressing the multisectoral impact of pressure injuries in the USA, UK and abroad. *BMJ Quality & Safety*, 2018 Mar;27(3):171-173. PMID: 28928166.
11. McQueen RB, Padula WV, Campbell JD. A Call for Open-Source Cost-Effectiveness Analysis. *Annals of Internal Medicine*, 2018 Apr 3;168(7):528-529. PMID: 29610902.
12. Padula WV<sup>\*†</sup>, Black JM. The Standardised Pressure Injury Prevention Protocol (SPIPP) for Improving Nursing Compliance with Best Practice Guidelines. *Journal of Clinical Nursing*, 2019 Feb;28(3-4):367-371. PMID: 30328652.
13. Padula WV<sup>\*†</sup>. The US Should Assess the Economic Value of Drugs Rather Than Leave it Up to Other Countries. *STAT News*, January 17, 2019.
14. Padula WV<sup>\*†</sup>, McQueen RB. Expanding the Role of the Patient-Centered Outcomes Research Institute: Reauthorization and Facilitating Value Assessments. *Applied Health Economics & Health Policy*, 2019 Dec;17(6):757-759. PMID: 31586307.
15. Padula WV, Ford HE Jr. Understanding health care prices and value through transparency. *USA Today* [Commercial Appeal], January 7, 2020.

16. **Padula WV**, Mishra MK. A healthcare draft could help unemployment and front line burden in response to COVID-19. *The Hill*, April 8, 2020.
17. **Padula WV**. Why only test symptomatic patients? Consider random testing for COVID-19. *Applied Health Economics & Health Policy*. 2020 Jun;18(3):333-334. PMID: 32266703.
18. Davidson PM, **Padula WV**, Daly J, Jackson D. Moral outrage in COVID19 – Understandable but not a strategy. *Journal of Clinical Nursing*, 2020 Oct;29(19-20):3600-3602. PMID: 32369649.
19. Armstrong DG, Swerdlow M, Armstrong AA, Conte MS, **Padula WV**, Bus S. “5-year Morality and Direct Costs of Care for People with Diabetic Foot Complications are Comparable to Cancer”, *Journal of Foot & Ankle Research*, 2020 Mar;13(1):16. PMID: 32209136
20. **Padula WV**, Trish E. Global budgets offer financial cushion amid the coronavirus pandemic. *Modern Healthcare*, May 18, 2020.
21. Jackson D, Anders R, **Padula WV**, Daly J, Davidson PM. Vulnerability of nurses and physicians with COVID-19: Monitoring and surveillance needed. *Journal of Clinical Nursing*, 2020 Oct;29(19-20):3584-3587. PMID: 32428345
22. **Padula WV**<sup>†</sup>, Reid NM. Wound, Ostomy and Continence Nurses Could be an Answer to the Economic Impact of Coronavirus. *J Wound Ostomy Continence Nursing*, 2020 Sep/Oct;47(5):523-524. PMID: 32970039
23. **Padula WV**<sup>†</sup>. Applying Value Assessment to the Health Care Sector for COVID-19. *Health Affairs Blog*, October 21, 2020.
24. **Padula WV**<sup>‡</sup>, Parasraumpuria S, Socal M, Conti RM, Anderson. Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) as Associated Budget Impact in the US.” *PharmacoEconomics*, 2020 Dec;38(12):1375-1376. PMID: 33164127
25. Dai T, Zaman MH, **Padula WV**, Davidson PM. Supply Chain Failures Amid Covid-19 Signal a New Pillar for Global Health Preparedness. *Journal of Clinical Nursing*, 2021 Jan;30(1-2):e1-e3. PMID: 32620038
26. **Padula WV**<sup>†</sup>, Steinberg I. What current and missing data can teach us about medication errors. *BMJ Quality & Safety*, 2021 Feb;30(2):89-91. PMID: 32978321
27. **Padula WV**<sup>†</sup>, Reid N, Tierce J. Health Technology Assessment for COVID-19 Treatments and Vaccines: Will Cost-effectiveness Analysis Serve Our Needs? *Value & Outcomes Spotlight*, 2021 Jan/Feb.
28. **Padula WV**<sup>†</sup>, Berke C, Bryant R. A Collaborative Call for Changes in Reimbursement Policies to Achieve Improvements in Hospital Safety Related to Pressure Injuries. *Journal of Patient Safety*, 2021 Jun;17(4):e268.
29. **Padula WV**<sup>†</sup>. Valuing Cures: Not If, But When? *Value in Health*, 2021 Jun;24(6):753-754.
30. Dietz DW, **Padula WV**<sup>‡</sup>, Zheng H, Pronovost PJ. To Improve the Value of Surgical Care, Focus Innovation on Elimination of Defects in Value. *New England Journal of Medicine*, November, 3, 2021.
31. **Padula WV**<sup>†</sup>, Pronovost PJ. Value Defects in the Health Services Sector. *Health Affairs Blog*, May 4, 2022.
32. Beaudin-Seiler B, Ma S, **Padula WV**, Neumann PJ, Ollendorf D. Moving Toward Broader Value: Expanding Value Assessment Beyond Clinical Drug Trial Data. *Health Affairs Blog*, June 22, 2022.
33. **Padula WV**<sup>†</sup>, Pronovost PJ. Improvements in Hospital Adverse Event Rates: Achieving Statistically Significant and Clinically Meaningful Results. *JAMA*, 2022 Jul;328(2):148-150. PMID: 35819434.



34. **Padula WV\***, Pronovost PJ. Improvements in Hospital Adverse Event Rates Among Hospitalized Patients – Reply. *JAMA*, 2023 Jan;329(4):344. PMID: 3669256.
35. Kottner J, Clark M, Black JM, **Padula WV\***, Worsley PR. Re: “How should clinical wound care and management translate to effective engineering standard testing requirements from foam dressings? Mapping the existing gaps and needs” by Gefen et al. *Advances in Wound Care*, 2023 Feb 13. PMID: 36476038.
36. **Padula WV\***, Black JM, Garcia A, Mishra MK. Congress Take a Positive Swing at an Unsung Public Health Crisis: Preventing Pressure Injuries in VA Facilities. *Advances in Skin & Wound Care*, 2023 Mar;36(3):123-124. PMID: 36806272.
37. **Padula WV\***, Reid NM, McQueen RB. Addressing Value Defects From Wasteful Services Through Health Technology Assessment. *Health Affairs Forefront*, March 6, 2023.

## Books

1. **Padula WV\***. *Quality Improvement Interventions to Prevent Pressure Ulcers*. Saarbrücken, Germany: Scholars Press, 2014. (ISBN 978-3-639-71934-5)
2. Bishai D, Brenzel L, **Padula WV** (Ed.). *The Handbook of Applied Economics in Vaccines*. Oxford: Oxford University Press, 2023.

## Book Chapters

1. Conti RM, **Padula WV**, Larson RL. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the U.S. and E.U. In: Helhmann R, ed. *Chronic Myeloid Leukemia*. Germany: Heidelberg University Press, 2016.
2. **Padula WV\***, Berzon R, Mujuruh P, Meltzer DO. Comparative Effectiveness Research in Health Disparity Populations. In: Zhang X, ed. *The Science of Health Disparities Research and Applications*. Bethesda, MD: National Institutes of Health, 2019.
3. **Padula WV**, Black JM. Pressure Injuries & Falls. In: Wu AW, ed. *Operational Guidance: Ensuring patient safety during outbreaks, epidemics and pandemics*. Geneva: World Health Organization, 2023.

## U.S. Patents

1. The Orthorotator: U.S. Patent #6135931, 24 October 2000. A teaching aid for stroke survivors with difficulty walking. Patients show immediate improvement.
2. The Cubic Internal Combustion Engine: U.S. Pat. Pend. #60/606572, 02 September 2004. Redesign of engine block, pistons, cam shaft, sleeves. 38% more efficient than conventional engine, and reduced use of materials.
3. The Reverse Hand Orthosis: U.S. Pat. Pend. #60/773201, 15 February 2006. A physical therapy device designed to correct contractions of the hemi paretic hand and fingers, and wrist muscles.
4. Progressive Enhanced Visual Field Prism: US Patent #20080137033, 12 June 2008. Application of yoked prisms for correction of visual midline shift.
5. Gait-Balance Analyzer: US Patent #20100262046-A1, 14 October 2010. Apparatus for analyzing gait and balance to determine visual-spatial distortion.

## Research Finding Dissemination

1. "Societal and policy implications of provider coverage for primary and preventive care in the U.S. transgender population: a cost-effectiveness analysis"
  - Quoted in: Beck J. "Covering Transgender Care Is Good Economics for Insurance Companies." *The Atlantic*, December 1, 2015.
  - Quoted in: Rinkunas S. "Insurance Companies Can't Afford Not to Cover Transgender Patients." *New York Magazine*, December 1, 2015.
  - Quote in: Preidt R. "Transgender Transition Costs Make Economic Sense: Study." *US New & World Report*, December 4, 2015.
  - Radio Interview: *The Dr. Leigh Vinocur Show*, Radio MD ([www.radiomd.com](http://www.radiomd.com)), December 5, 2015.
  - Quoted in: The Editorial Board. "No Reason to Exclude Transgender Medical Care." *The New York Times*, December 9, 2015.
  - Quoted in: Dayan E, Molina B. "Policy Changes in the Transgender Healthcare Arena." *Physician*, Kevin MD ([www.kevinmd.com](http://www.kevinmd.com)), January 5, 2017.
2. "Cost-effectiveness of Tyrosine Kinase Inhibitors Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After U.S. Generic Entry of Imatinib"
  - Quoted in: Weintraub A. "Generic Gleevec Will Hurt Novartis – But Save Millions In Health Costs." *Forbes*, March 16, 2016.
  - Quoted in: Preidt R. "Generic Gleevec Will Likely Save Millions in Costs." *WebMD News*, March 18, 2016.
3. "Cost-Benefit Analysis of a Support Program for Nursing Staff"
  - Quoted in: Brownlee C. "Helping Clinicians Through Traumatic Events Also Helps the Bottom Line, Cost-Benefit Analysis Shows." *JHU Hub*, May 10, 2017.
  - Cited in: Connors C. "Peer Counseling for Clinicians provides immediate support – and pays off for the hospital." *STAT News*, July 21, 2017.
4. "The Effectiveness and Value of Prophylactic Five-Layer Foam Sacral Dressings to Prevent Hospital-acquired Pressure Injuries in Acute Care Hospitals"
  - Quoted in: Finn K. "For pressure injuries, prevention is the key." *MedTech Views*, July 10, 2017.
  - Quoted in: "Prophylactic Dressings Reduce Pressure Injuries." *OR Today*, December, 2017.
5. "The US Should Assess the Economic Value of Drugs Rather Than Leave it Up to Other Countries"
  - Quoted in: "International Pricing Index Intrigue." *W2O Group*, January 18, 2019.
  - Quoted in: "Opinion: US Shouldn't Outsource Drug Value Assessments Through An IPI." *HealthEconomics.com*, January 21, 2019.
6. "The Opioid Crisis"
  - Quoted in: Thompson D. "Is Pharmacotherapy Enough to Manage the Opioid Crisis?" *ISPOR Value & Outcomes Spotlight*, February, 2019.
7. "Teaching Vaccine Economics Everywhere"
  - Quoted in: Myers K. "Anti-vaxxers are costing Americans billions each year." *Yahoo! Finance*, April 20, 2019.
8. "Adverse Effectives of the Medicare PSI-90 Hospital Penalty System on Revenue-Neutral Hospital-acquired Conditions"
  - Quoted in: Castellucci M. "As pressure injuries climb, debate arises over whether some are avoidable." *Modern Healthcare*, November 4, 2019.

9. "Five-layer border dressings as part of a quality improvement bundle to prevent pressure injuries in US skilled nursing facilities and Australian nursing homes"
  - Quoted in: Marselas K. "Border dressing payoff for both patients and providers." *McKnights Long Term Care News*, October 17, 2019.
10. "Understanding health care prices and value through transparency"
  - Reprinted in: *The Tennessean*, January 8, 2020.
  - Reprinted in: *Knoxville News*, January 8, 2020.
  - Reprinted in: *Jackson Sun*, January 8, 2020.
  - Reprinted in: *Leaf Chronicle*, January 8, 2020.
  - Reprinted in: *Rama on Healthcare*, January 8, 2020.
  - Reprinted in: *Kaiser Health News*, January 8, 2020.
11. "The Standardized Pressure Injury Prevention Protocol (SPIPP)"
  - Quoted in: Black J. Pressure Ulcers: Surgery's Sore Subject. *Outpatient Surgery*, January, 2020.
  - Quoted in: Todd J. Pressure Injury Guidelines: a look back and review of what's new. *Medline: Operational Performance*, January 2020.
12. Coronavirus Disease 2019 (COVID-19) Outbreak
  - Quoted in: Weintraub K. Not Just Ventilators: Staff Trained to Run Them Are in Short Supply. *Scientific American*, April 8, 2020.
  - Quoted in: Cart J. Wear a Mask! OK, but what kind? *Cal Matters*, April 4, 2020.
13. "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and the Associated Budget Impact in the U.S."
  - Quoted in: Ferreri D. Orphan Drug Exclusivity Keeping Biosimilars off the Market, Study Says. *AJMC – The Center for Biosimilars*, June 25, 2020.
14. "State and Federal Policy Solutions to Rising Prescription Drug Prices in the U.S."
  - Quoted in: Chung J, Kaufman A, Rauenzahm B. Regulating Prescription Drug Costs. *The Regulatory Review*, October 17, 2020.
15. Pressure Injuries in COVID-19 Patients
  - Quoted in: Rodriguez A. Bedsores Kill over 60K people in the US each year. Amid COVID, experts worry more may be at risk. *USA Today*, November 18, 2020.
16. COVID-19 Vaccine Distribution in California
  - Quoted in: DeRuy E, Kelliher F, Moore S. COVID: Will revolt over Blue Shield cost Santa Clara County access to Vaccine? *The Mercury News*, March 9, 2021.
  - Interviewed by: Nguyen C. ABC News 7: Eyewitness Report. *KGO TV San Francisco*, March 10, 2021.
  - Quoted in: Kelliher F, DeRuy E. Tensions mount over California's vaccine distribution plan. *East Bay Times*, March 10, 2021.
  - Interviewed by: Baird J. CBS2 News This Morning: Special Report. *KCAL9 Los Angeles*, March 11, 2021.
  - Quoted in: Savidge N. COVID vaccines: Will California meet Bien's May 1 goal? *The Mercury News*, March 12, 2021.
  - Quoted in: DeRuy E. COVID: Bay Area counties agree to vaccine distribution plan after weeks of squabbles with state over Blue Shield deal. *The Mercury News*, March 24, 2021.

- Quoted in: Savidge N, Woolfolk J. COVID: California puts J&J vaccine on hold. *The Mercury News*, April 13, 2021.

#### 17. COVID-19 Supply Chain Issues

- Quoted in: Hwang K. Supply Chain Woes Trigger Shortages of Critical Medical Devices. *CalMatters*, November 22, 2021.
- Interviewed by: Mizuguchi K. ABC News 7: Eyewitness Report. *KQED Public Radio, Los Angeles*, November 23, 2021.

#### 18. Improvements in Hospital Adverse Event Rates

- Quoted in: Melillo G. US hospitals are safer for patients than a decade ago, but more work remains: study. *The Hill*, July 12, 2022.
- Quoted in: Kania K. Care for heart patients shows considerable improvement, but ‘bold reforms’ still necessary. *Cardiovascular Business*, July 14, 2022.

#### 19. Increased Nursing Wages

- Quoted in: CBSLA Staff. Nurses picket outside Grand Park Convalescent Hospital over payment of wages. *CBS News (Los Angeles)*, August 30, 2022.

#### 20. Machine Learning and Artificial Intelligence

- Quoted in: Vedantam K. AI Could Transform Medical Imaging – So Why Don’t We See It More? *Crunchbase*, November 28, 2022.

#### 21. Inaccuracy of PulseOximetry Monitoring during the COVID-19 Pandemic

- Quoted in: Short E. Pulse Oximetry Inaccuracies Delayed COVID-19 Treatment — Black patients more likely to have an unrecognized need for therapy versus white patients. *MedPage Today*, August 24, 2023.

## RESEARCH GRANT PARTICIPATION

### Pending

Eliciting Patient Preferences for Estimating Novel Value Elements in the Conduct of Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Analysis of Cancer Outcomes

1160962, PhRMA Foundation

4/2024

Principal Investigator: W. Padula

Grant Objective: To apply GRACE methods to treatments for breast cancer and prostate cancer to quantify patients' relative-risk aversion over consumption and estimate GRACE parameters.

Role: PI

Award: \$500,000 (15% FTE)

### Active

Pre-Doctoral Fellowship in Health Economics

015236-00001, Bristol-Myers Squibb

6/2022-5/2024

Principal Investigator: W. Padula

Grant Objective: Support Fellowship Training for BMS fellows (Jiafan Chen).

Role: PI

Award: \$99,000 (10% FTE)

Pre-Doctoral Fellowship in Health Economics

013727-00001, Bristol-Myers Squibb

6/2021-5/2024

Principal Investigator: W. Padula

Grant Objective: Support Fellowship Training for BMS fellows (Hanke Zheng, Jenny Lam).

Role: PI

Award: \$188,000 (20% FTE)

Evaluate Treatments and Outcomes in Patients with NSCLC and Multiple Myeloma

4201481918, AbbVie

7/2020-6/2024

Principal Investigator: W. Padula

Grant Objective: Support Fellowship Training for Abbvie fellows (Sam Crawford, Tony Yu).

Role: PI

Award: \$282,000 (20% FTE)

### Completed

Postdoctoral Fellowship

T32 HS000078-17, AHRQ National Research Service Award

2013

Principal Investigators: D. Meltzer and J. Holl

Grant Objective: General Postdoctoral Training

Role: Trainee

Award: \$58,000 (100% FTE)

Using EHR Data to Dynamically Target Patients for Braden Scale Risk-assessment  
F32 HS023710-01, AHRQ National Research Service Award  
2014-2015

Co-Sponsors: D. Meltzer and R. Gibbons

Grant Objective: Using EHR Data to Dynamically Target Patients for Braden Scale Risk-assessment

Role: Trainee

Award: \$207,906 (100% FTE)

Workflow Modeling of Physician-Scientist Workforce  
N27 6201300089U, NIH Office of the Director  
2015-2016

Principal Investigators: D. Meltzer and M. Heggeness

Grant Objective: Agent-based model of NIH-funded physician-scientists

Role: Modeler

Award: \$30,000 (25% FTE)

Cost-effectiveness analysis of Rales Health Center Model  
Rales Center at Johns Hopkins Medicine  
2015-2016

Principal Investigators: W. Padula and S. Johnson

Grant Objective: Develop Cost-effectiveness Model of Rales Health Center at Kipp School in  
Baltimore, MD

Role: co-PI

Award: \$20,000 (10% FTE)

Cost-effectiveness analysis of Cardiovascular Disease Model  
Welch Center at Johns Hopkins Medicine  
2015-2016

Principal Investigator: W. Padula and L. Cooper

Grant Objective: Develop Cost-effectiveness Model of Public Health Intervention for Cardiovascular  
Disease in Baltimore, MD

Role: co-PI

Award: \$20,000 (5% FTE)

Medicare Benefit Redesign Options: Meeting the Needs of Future Beneficiaries  
The Commonwealth Fund  
2015-2016

Principal Investigator: K. Davis

Grant Objective: The purpose of this study is to evaluate the elasticity of demand for healthcare  
utilization for varying rates of copayment among Medicare beneficiaries.

Role: Co-I

Award: \$395,515 (10% FTE)

The Value of Novel Therapies for the Treatment of Hepatitis C in an Integrated Health Care System  
Kaiser-Permanente and Johns Hopkins Research Collaborative  
2016-2017

Principal Investigator: W. Padula and C. Rodriguez

Grant Objective: Develop Cost-effectiveness Model of Policies for the delivery of Hepatitis C  
treatments

Role: PI

Award: \$86,000 (5% FTE)

Cost-effectiveness Analysis of Treatment for Restless Leg Syndrome  
Restless Leg Syndrome Foundation  
2016-2017

Principal Investigator: W. Padula

Grant Objective: To perform a cost-effectiveness analysis of physician treatment for Restless Leg Syndrome in a society where there is board certification.

Role: PI

Award: \$35,000 (10% FTE)

Who Should Pay for Drugs When the Medicare Beneficiary Has Reached Catastrophic Limit?  
The Commonwealth Fund  
2016-2017

Principal Investigator: G. Anderson

Grant Objective: The purpose of this study is to evaluate the budget impact of cost-sharing between Medicare, private drug plans and beneficiaries for high-cost specialty drugs

Role: Co-I

Award: \$100,000 (10% FTE)

Controlling Drug Spending: Four Action Steps that will Promote Policy Change  
The Laura & John Arnold Foundation  
2016-2018

Principal Investigator: G. Anderson

Grant Objective: The purpose of this study is to evaluate policies that will help control drug spending.

Role: Co-I

Award: \$4,500,000 (25% FTE)

Teaching Vaccine Economics Everywhere  
The Bill & Melinda Gates Foundation  
2017-2018

Principal Investigator: D. Bishai

Grant Objective: The purpose of this grant is to develop an economic evaluation curriculum in global vaccine economic evaluation.

Role: Co-I

Award: \$1,500,000 (25% FTE)

A Longitudinal Population Based Study that Examines Discrimination Health and Work  
U.S. Social Security Administration, The Sandell Grant Program  
2017-2018

Principal Investigator: E. Gonzales

Grant Objective: The purpose of this grant is to explore the relationships between discrimination, health, retirement expectations and labor force participation in middle-aged African Americans using data from the Health and Retirement Study.

Role: Co-I

Award: \$45,000 (5% FTE)

Methods for Quality Improvement and Economics Evaluation of Pressure Ulcer Prevention  
Molnlycke Health Care  
2018

Principal Investigator: W. Padula

Contract Objective: Developing educational programming and training in quality improvement methods for commercialization in partnership with The Armstrong Institute for Patient Safety & Quality at Johns Hopkins Medicine

Role: PI

Award: \$40,000 (10% FTE)

Exploring synergies of HEOR/CER methods with PCORI  
PhRMA  
2019

Principal Investigator: W. Padula and R. B. McQueen

Grant Objective: The purpose of this grant is to develop a paper series on future roles of PCORI in health services research to achieve funding reauthorization.

Role: Co-PI

Award: \$40,000 (10% FTE)

Investigating the value-added of High-cost Health Services in the U.S.  
011861-00001, PhRMA Foundation  
2019-2020

Principal Investigator: W. Padula and J.W. Hay

Grant Objective: The purpose of this grant is to develop a paper series on role of value assessment to improve U.S. management of high-value healthcare.

Role: Co-PI

Award: \$55,000 (30% FTE)

Creating the Architecture for Sustainable Immunization Financing  
AWD-00003545, The Bill & Melinda Gates Foundation  
2019-2021

Principal Investigator: D. Bishai

Grant Objective: To develop an economic evaluation curriculum in global vaccine economics.

Role: Site PI

Award: \$26,122 (10% FTE)

Preventing Pressure Ulcers with Repositioning Frequency and Precipitating Factors, the "TEAM-UP" trial  
R01 NR016001, NIH NINR  
2019-2021

Principal Investigator: T. Yap and S. Kennerly

Grant Objective: The purpose of this grant is to develop an economic evaluation of different repositioning protocols for pressure injury prevention

Role: Co-I

Award: \$58,734 (15% FTE)

Teaching Vaccine Economics Everywhere  
2004234550, The Bill & Melinda Gates Foundation  
2021

Principal Investigator: D. Bishai

Grant Objective: The purpose of this grant is to write and edit a textbook on Vaccine Economics to publish as part of the Oxford University Press (OUP) health economics text book series.

Role: Site PI

Award: \$21,000 (10% FTE)

Pressure Ulcer Research on Patient-centered Outcomes and Stakeholder Engagement (PURPOSE)  
KL2 TR001854, NIH OER  
2020-2023

Principal Investigator: W. Padula

Grant Objective: The purpose of this grant is to predict hospitalized patients with heightened pressure ulcer risk using machine learning. I will leverage information from the EHR data warehouse at Keck Medicine to plan integration of a CDS tool to modernize hospital safety in pressure injury prevention.

Role: PI

Award: \$517,000 (75% FTE)



Comparing Value Assessment Measurements Derived from Classical Cost-effectiveness Analysis vs. Generalized Risk-adjusted (GRACE) Methods with the Elicitation of Patient Preferences  
014890-00001, PhRMA Foundation, Value Assessment Initiative  
2022-2023

Principal Investigator: W. Padula

Grant Objective: Our objective is to compare findings about the value of mCRPC treatments using ICER and GRACE approaches.

Role: PI

Award: \$100,000 (10% FTE)

## TEACHING

### Advisees

- 2015 Andrew Millis, The University of Chicago. Degree: M.D.
- 2015 – 2017 Jeromie Ballreich, The Johns Hopkins University. Degree: PhD (Health Economics)  
Thesis: Price Discrimination in the US Cancer Drug Market.
- 2015 – 2016 Josiah Mueller RN, The Johns Hopkins University. Degree: MHS (Health Economics)  
Thesis: Determining the Value of a Comprehensive Primary and Preventive Care Model for School-Based Health Centers: A Cost-Benefit Analysis.
- 2015 – 2016 Maxwell Thayer, The Johns Hopkins University. Degree: MSPH
- 2016 Uchenna Onyekwere, The Johns Hopkins University. Degree: MPH
- 2015 – 2016 Ya-Hsuan Chiang B.Pharm, The Johns Hopkins University. Degree: MPH  
Thesis: Improving Analytic Throughput of Treatment Options for Non-Small Cell Lung Cancer: A Cost-effectiveness Analysis.
- 2015 – 2016 Jonathan Hong MD, The Johns Hopkins University. Degree: MHS (Health Economics)  
Thesis: Community Care Management as a Population Health Intervention to Reduce Disparities and Control Hypertension in Primary Care: A Cost-effectiveness Analysis.
- 2015 – 2016 Madhu Nagarajan MBBS, The Johns Hopkins University. Degree: MPH  
Thesis: Societal Impact of One-time Screening for Diabetes at age 30 in the Indian Population: A Cost-effectiveness Analysis.
- 2015 – 2016 Bing Xie, The Johns Hopkins University. Degree: MHS (Health Economics)  
Thesis: Allocating Provider Resources to Accurately Diagnose and Treat Restless Leg Syndrome: A Cost-effectiveness and Budget Impact Analysis.
- 2015 – 2017 Dane Moran, The Johns Hopkins University. Degree: MD/MPH
- 2016 – 2017 Matthew Kaufmann, The Johns Hopkins University. Degree: MHS (Health Economics)  
Thesis: Cost-effectiveness Analysis of a School-Based Health Center.
- 2016 – 2017 Sabrina Rahman, The Johns Hopkins University. Degree: MPH  
Thesis: Cost Effectiveness of Resection vs. Serial Dilatation for Treating Laryngotracheal Stenosis.
- 2016 – 2017 Julia Allen, The Johns Hopkins University. Degree: MPH  
Thesis: Cost-effectiveness Analysis of Feeding Guidelines for Neonatal Patients Following Gastrointestinal Surgery.
- 2016 – 2017 Matthew Lucci, The Johns Hopkins University. Degree: MPH  
Thesis: What is the Incremental Cost of Hospital-acquired Pressure Ulcers in the United States.
- 2016 – 2017 Hui-Han "Bruce" Chen, The Johns Hopkins University. Degree: MHS (Health Economics)  
Thesis: The Choice of the Willingness-to-Pay Threshold and Its Impact on Cost-Utility Analysis.
- 2017 – 2018 Yutong Harriet Chen, The Johns Hopkins University. Degree: MHS (Health Economics)  
Thesis: Cost-effectiveness of Sacral Dressings for Pressure Injury Prevention in Nursing Homes in the U.S. and Australia.
- 2017 – 2018 Ellen Hu, The Johns Hopkins University. Degree: MHS (Health Economics)  
Thesis: Cost-effectiveness of Employee Training and Education to Reduce Addiction to Prescription Opioids in Baltimore.
- 2017 – 2018 Rahul Chander, The Johns Hopkins University. Degree: MHS (Health Economics)  
Thesis: Cost-utility of the Johns Hopkins Hospital RISE Program

- 2017 – 2018 Sreelekshmi Rajeswari, The Johns Hopkins University. Degree: MHS (Health Economics)  
Thesis: Cost-effectiveness of Spinraza to Treat MSA.
- 2017 – 2018 Vinayak Bhardwaj, The Johns Hopkins University. Degree: MPH  
Thesis: Cost-effectiveness of the Corrie Application to prevention readmission caused by acute myocardial infarction.
- 2017 – 2018 Eric Wan, The Johns Hopkins University. Degree: MBA/MPH  
Thesis: Cost-effectiveness of Transitional Care for Transgender People in the U.S. Military.
- 2017 – 2018 Jenny Lee, The Johns Hopkins University. Degree: MBA/MPH  
Thesis: Cost-effectiveness of Microbiome Screening for Immuno-oncological Therapies.
- 2017 – 2018 Leslie McAhern, The Johns Hopkins University. Degree: MPH  
Thesis: The Impact of Stress on Physician Attrition in U.S. Health Systems.
- 2015 – 2018 Taruja Karmarkar (Co-Advisor with Darrell Gaskin), The Johns Hopkins University.  
Degree: PhD (Health Economics)  
Thesis: The Value of Novel Therapies for the Treatment of Hepatitis C in An Integrated Health Care System.
- 2015 – 2018 Natalie Reid, The Johns Hopkins University. Degree: PhD (Health & Social Policy)  
Thesis: American's Preference for Food Characteristics and Their Role in Policy.
- 2015 – 2018 Melissa Sherry, The Johns Hopkins University. Degree: PhD (Health Services Research)  
Thesis: Neighborhood Factors, Health Outcomes and How Their Intersection May Hold the Key to Reducing Healthcare Costs.
- 2016 – 2018 Kellan Baker, The Johns Hopkins University. Degree: PhD (Health Services Research)
- 2019 Kinpritma Sangha, University of Southern California. Degree: PhD (Health Economics)  
Thesis: Impact of Diagnostic Testing on Pediatric Patients with Pharyngitis: Evidence from a Large Health Plan
- 2018 – 2020 Jonathan Salcedo, University of Southern California. Degree: PhD (Health Economics)  
Thesis: The Lifetime Costs of Sickle Cell Disease in the United States
- 2018 – 2020 Hsin-Yun Yang, University of Southern California. Degree: PhD (Health Economics)  
Thesis: The Disease Burden Among Aging People Living with HIV/AIDS.
- 2019 – 2020 Si Xuan, University of Southern California. Degree: PhD (Health Economics)  
Thesis: Pharmacotherapy among patients with Type 2 Diabetes.
- 2019 – 2022 Roxanna Seyedin, University of Southern California. Degree: PhD (Health Economics)  
Thesis: Impact of Medication Persistence on Clinical and Healthcare Outcomes in Patients with Major Depressive Disorder.
- 2019 – 2022 Samuel Crawford, University of Southern California. Degree: PhD (Health Economics)  
Thesis: Evaluating Treatment Options for Metastatic Castration-Resistant Prostate Cancer: A Comprehensive Value Assessment and Applications of GRACE
- 2019 – 2022 Marcella Kelley, University of Southern California. Degree: PhD (Health Economics)  
Thesis: The effect of nudges, setting and provider history on outpatient prescribing
- 2019 – present Hanke Zheng, University of Southern California. Degree: PhD (Health Economics)

### **Preliminary Oral Participation**

- 2015 Departmental Oral Exam, Jeromie Ballreich, Johns Hopkins University (Alternate)
- 2015 School-wide Oral Exam, Jeromie Ballreich, Johns Hopkins University (Alternate)
- 2016 School-wide Oral Exam, Christina Garcia, Johns Hopkins University (Alternate)
- 2016 Departmental Oral Exam, Mo Zhou, Johns Hopkins University

- 2016 School-wide Oral Exam, Mo Zhou, Johns Hopkins University
- 2016 Departmental Oral Exam, Taruja Kumarkar, Johns Hopkins University
- 2016 School-wide Oral Exam, Taruja Kumarkar, Johns Hopkins University
- 2016 Departmental Oral Exam, Natalie Reid, Johns Hopkins University
- 2017 School-wide Oral Exam, Natalie Reid, Johns Hopkins University
- 2017 Departmental Oral Exam, Melissa Sherry, Johns Hopkins University
- 2017 School-wide Oral Exam, Thitipong Tankumpuan, Johns Hopkins University
- 2017 School-wide Oral Exam, E. Wangeci Kagucia, Johns Hopkins University
- 2017 School-wide Oral Exam, Melissa Sherry, Johns Hopkins University
- 2018 School-wide Oral Exam, Binu Koirala, Johns Hopkins University
- 2018 Departmental Oral Exam, Allison Oakes, Johns Hopkins University (Alternate)
- 2018 School-wide Oral Exam, Allison Oakes, Johns Hopkins University
- 2019 Departmental Oral Exam, Hsin-Yun Yang, University of Southern California
- 2019 Departmental Oral Exam, Jonathan Salcedo, University of Southern California
- 2019 Departmental Oral Exam, Si Xuan, University of Southern California
- 2020 Departmental Oral Exam, Roxanna Seyedin, University of Southern California
- 2020 Departmental Oral Exam, Elmar Aliyev, University of Southern California
- 2021 Departmental Oral Exam, Samuel Crawford, University of Southern California (Chair)
- 2021 Departmental Oral Exam, Marcella Kelley, University of Southern California
- 2023 Departmental Oral Exam, Hanke Zheng, University of Southern California (Chair)

**Final Oral Participation**

- 2017 Jeromie Ballreich, Johns Hopkins University (Alternate)
- 2017 Ellen Janssen, Johns Hopkins University (Alternate)
- 2017 Mo Zhou, Johns Hopkins University (Alternate)
- 2018 Taruja Karmarkar, Johns Hopkins University
- 2018 Christina Garcia, Johns Hopkins University
- 2018 Natalie Reid, Johns Hopkins University
- 2018 Thitipong Tankumpuan, Johns Hopkins University
- 2019 Binu Koirala, Johns Hopkins University
- 2019 Kinpritma Sangha, University of Southern California
- 2020 Jonathan Salcedo, University of Southern California
- 2020 Hsin-Yun Yang, University of Southern California (Chair)
- 2020 Si Xuan, University of Southern California
- 2022 Roxanna Seyedin, University of Southern California (Chair)
- 2022 Samuel Crawford, University of Southern California (Chair)
- 2022 Marcella Kelley, University of Southern California (Chair)

## CLASSROOM INSTRUCTION

### Principal Instructor

- 2015 CCTS 46003: Advanced Healthcare Quality Improvement  
Enrollment: 15  
Credits: 0.5  
Institution: The University of Chicago  
Description: Course Director and Lecturer on advanced methods (i.e. study design, statistical analysis, economics) for quality improvement using the clinical microsystems approach in 10-week (0.5 credit) course
- 2016 - 2018 JHSPH 313.631.01: Economic Evaluation II  
Enrollment: 80  
Credits: 3.0  
Institution: The Johns Hopkins Bloomberg School of Public Health  
Description: Course Director and Lecturer on cost-effectiveness analysis modeling in Microsoft Excel and TreeAge in 8-week (3 credit) course at Johns Hopkins Bloomberg School of Public Health; 2016 Winter, 2017 Winter; Baltimore, MD
- 2019 - 2021 PMEP 535: Behavioral Science & Policy in Healthcare  
Enrollment: 10  
Credits: 4.0  
Institution: University of Southern California  
Description: Course Director and Lecturer on 16-week (4 credit) course about behavioral science and economic principles applied to health policy and health system quality improvement.
- 2020 - present PHRD 508: Pharmacy Literature  
Enrollment: 200  
Credits: 4.0  
Institution: University of Southern California  
Description: Course Co-Director and Lecturer on 16-week (4 credit) course about comprehending pharmacy/medical literature and performing health analytics.
- 2021 PMEP 526: PharmacoEconomics II  
Enrollment: 10  
Credits: 4.0  
Institution: University of Southern California  
Description: Course Director and Lecturer on 16-week (4 credit) course about PharmcoEconomic theory and principles for application.
- 2021 PMEP 527: PharmacoEconomics III  
Enrollment: 10  
Credits: 4.0  
Institution: University of Southern California  
Description: Course Director and Lecturer on 16-week (4 credit) course about Economic Modeling using methods in Economic Evaluation.
- 2023-2024 PMEP 525-526: PharmacoEconomics I & II  
Enrollment: 5  
Credits: 8.0  
Institution: University of Southern California  
Description: Course Director and Lecturer on 323-week (8 credit) course about Economic Modeling using methods in Economic Evaluation.

## Other Significant Teaching

- JHSPH 313.630.01: Economic Evaluation I (Course Director: Greg de Lissovoy, PhD). Regular lecturer in this introductory course on economic evaluation theory and methods. Accrued Lectures: 2
- JHSPH 313.861.01: Public Health Economics Seminar (Course Director: Darrell Gaskin, PhD). Regular lecturer in this 1 credit course for MHS graduate students in Health Economics, 2015-present. Accrued Lectures: 2
- JHSPH 313.632.01: Economic Evaluation III (Course Director: Greg de Lissovoy, PhD). Lecturer in this 3 credit course on budget impact analysis modeling in excel. Accrued Lectures: 2
- JHSPH 312.861.01: MHA Care Competition (Course Director: Doug Hough, PhD). Case Study Mentor to Competition Teams. Accrued Lectures: 1
- JHSPH 700.623.01: Ethics of Healthcare Decision Making (Course Director: Zack Berger, MD, PhD). Lecturer on influence of health economics on medical ethics. Accrued Lectures: 2
- JHSPH 300.713.01: Research and Evaluation Methods for Health Policy I (Course Directors: Renan Castillo, PhD and Cassandra Crifasi, PhD). Lecturer on Controversies in Economic Evaluation Methods. Accrued Lectures: 3
- JHAS 280.340.01: Fundamentals of Health Policy & Management (Course Director: Darrell Gaskin, PhD). Lecturer on Introduction to Cost-effectiveness Analysis. Accrued Lectures: 1
- JHSPH 300.721.01: PhD Seminar in Health Policy I (Course Director: Colleen Barry, PhD and Brendan Solaner, PhD). Lecturer on Cost-effectiveness Analysis and Economic Evaluation. Accrued Lectures: 1
- Vaccine Economic Evaluation (Course Directors: David Bishai, PhD; William Padula, PhD; Shreena Malaviya, MHS). Program for “Teaching Vaccine Economics Everywhere.” Locations: Boston, MA; Johannesburg, ZA; Kampala, UG; Delhi, India; Abu Dhabi, UAE. Accrued Workshops: 7
- USC PMEP 539: Economic Assessment of Medical Care (Course Director: Joel Hay, PhD). Lecturer on Machine Learning Methods for Economic Evaluation. Accrued Lectures: 1.
- USC PMEP 509: Research Design (Course Director: Jeffrey McCombs, PhD). Lecturer on Interrupted Time Series and Quasi-Experimental Design. Accrued Lectures: 1
- USC PMEP 539: Research Design in Health Care (Course Director: Yuna Bae-Shaw, PharmD, PhD). Lecturer on Economic Evaluation in U.S. Healthcare. Accrued Lectures: 1

## ACADEMIC SERVICE

### University of Southern California

#### Center and Institute Affiliations

- Fellow, Leonard D. Schaeffer Center for Health Policy & Economics, 2019-present
- Scholar, Mentored Career Development in Clinical and Translational Science (MCD-CTS) Program, Southern California Clinical and Translational Science Institute (SC-CTSI), 2020-present

#### Department of Pharmaceutical & Health Economics

- Faculty Search Committee (Chair), Department of Pharmaceutical & Health Economics, 2022-23
- Faculty Search Committee, Department of Pharmaceutical & Health Economics, 2021-23
- Faculty Search Committee, MS in Healthcare Decision Analysis (MCDA) Program, 2020
- Admissions Committee, Graduate Program in Pharmaceutical & Health Economics, 2020-2022

School of Pharmacy

- ACPE Professional Experience Committee, 2021-2022
- AI/ML Research Retreat Committee, 2021
- Faculty Search Committee, Chair of Department of Clinical Pharmacy, 2021-2023
- Faculty Retreat Planning Committee, 2022
- Intramural Grant Review Committee, Machine Learning Track, 2022

**Johns Hopkins University**

Center and Institute Affiliations

- Center for Health Services and Outcomes Research (CHSOR), 2015-2018
- Roger C. Lipitz Center for Integrated Health Care, 2015-2018
- Center for Drug Safety & Effectiveness (CDSE), 2016-2018

Department of Health Policy & Management

- Admissions Committee, Ph.D. Program in Health Services Research & Policy, 2016-2018
- Admissions Committee, M.H.S. Program in Health Economics, 2016-2018
- Research Infrastructure Committee, CHSOR, 2016-2018
- Search Committee, Faculty in Economic Evaluation, 2017-2018

Bloomberg School of Public Health

- Core Faculty, Interdepartmental Program in Health Economics, 2015-2018

Johns Hopkins Medicine

- Core Faculty, The Armstrong Institute for Patient Safety and Quality, 2016-2019
- Co-Lead, Analytics Core, The Armstrong Institute Diagnosis Center, 2017-2018
- Adjunct Faculty, Division of General Internal Medicine, 2017-2018

Johns Hopkins Nursing

- Adjunct Faculty, School of Nursing, 2016-present

## PRESENTATIONS

### Named Lectureships, Keynotes, Plenaries & Symposiums

1. **Padula WV**. Applying Economic Evaluation to Plastic & Reconstructive Surgery. *Stanley A. Klatsky, M.D., Business Grand Rounds*. Department of Plastic & Reconstructive Surgery, Johns Hopkins Hospital; December 13, 2018, Baltimore, MD.
2. **Padula WV**. Gateway to Regulatory Compliance: Through the Looking Glass. Keynote Lecture, *National Pressure Ulcer Advisory Panel (NPUAP) Biannual Conference*; February 23, 2019, St. Louis, MO.
3. **Padula WV**. Improving the Quality of Pressure Injury Prevention: Lookout for Rabbit Holes. Keynote Lecture. *Wound Ostomy and Continence Nurses Society, Mid-Atlantic Region Annual Meeting*; September 13, 2019, Baltimore, MD.
4. **Padula WV**. Potential Economic & Policy Implications of the 2019 Guideline. Plenary Address. *National Pressure Ulcer Advisory Panel (NPUAP) 2019 International Guideline Launch*; November 15, 2019, Los Angeles, CA.
5. **Padula WV**, Pandya A, Reid R, Ford H Jr., Clemons T, Conti R. Lessons to Serve a Growing Purpose of Economic Evaluation in the U.S. in the 2020s. Symposium. *Society for Medical Decision Making (SMDM) Annual North American Meeting*; November 20, 2020, Chicago, IL.
6. **Padula WV**. NPIAP in 2020: Sharpening Your Clinical Edge. Plenary Address. *National Pressure Injury Advisory Panel (NPIAP) 2021 Annual Conference*; March 10, 2021 (virtual).
7. Yap T, **Padula WV**, Tzen YT. Pressure Injury Prevention: Using Technology to Address an Archaic Problem. Symposium. *National Pressure Injury Advisory Panel (NPIAP) 2021 Annual Conference*; March 11, 2021 (virtual).
8. Murphy G, **Padula WV**. Intersection of Policy & Practice. Plenary Address. *National Pressure Injury Advisory Panel (NPIAP) 2021 Annual Conference*; March 12, 2021 (virtual).
9. **Padula WV**. Skin Failure at End of Life. Plenary Address. *National Pressure Injury Advisory Panel (NPIAP) 2021 Fall Policy Conference*; November 19, 2021, Washington, DC.
10. **Padula WV**. NPIAP Vision 2030. Plenary Address. *National Pressure Injury Advisory Panel (NPIAP) 2022 Annual Conference*; March 17, 2022, Tampa, FL.
11. **Padula WV**. Defining Value in Wound Care. Symposium. *The Western Foot & Ankle Conference*; June 24, 2022, Anaheim, CA.
12. **Padula WV**. Complexity Bias in the Prevention of Adverse Events. Plenary Address. *SAWC Fall 2022*; October 15, 2022, Las Vegas, NV.

### Scientific Meetings

#### Oral Abstracts

1. **Padula WV**, Mishra MK, Makic MB, Sullivan PW. A Cost-Effectiveness Analysis of Pressure Ulcer Prevention. *21<sup>st</sup> Annual Rocky Mountain Regional Multidisciplinary Research & EBP Symposium*; March 2010, Denver, CO.
2. **Padula WV**. Cordero-Coma M, Yilmaz T. A Cost-effectiveness Analysis of Off-label Biologics to Treat Sarcoid Posterior Uveitis Versus Posterior Uveitis Versus Standard of Care: Comparing Infliximab to Methotrexate and Systemic Steroids. *University of Colorado Pharmaceutical Sciences Research Symposium*; January 18, 2012, Aurora, CO.



3. **Padula WV**. Comparative Effectiveness of Quality Improvement Interventions for Pressure Ulcer Prevention in Hospitals. *Wound Ostomy and Continence Nurses (WOCN) Society Annual Meeting*; June 24, 2014, Nashville, TN.
4. **Padula WV**. Are Evidence-based Practices Associated with Effective Prevention of Hospital-acquired Pressure Ulcers in U.S. Hospitals? *AcademyHealth Annual Research Meeting*, June 13, 2015, Minneapolis, MN.
5. **Padula WV**, Larson R, Conti R. Comparing Tyrosine Kinase Inhibitor Treatment Strategies for Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase when Imatinib Loses Patient Exclusivity in the U.S.: a cost-effectiveness Analysis. *International Health Economics Association (iHEA) Congress*; July 12, 2015, Milan, Italy.
6. **Padula WV**. Using EHR Data to Dynamically Predict Incidence of Hospital-acquired Pressure Ulcers. *Institute for Healthcare Improvement Scientific Symposium*; December 7, 2015, Orlando, FL.
7. **Padula WV**. Using Clinical Data to Monitor High-cost, Performance Coding Issues Associated with Pressure Ulcers. *Society for Advancement in Wound Care (SAWC) Young Investigator Awards Symposium*; April 16, 2016, Atlanta, GA.
8. **Padula WV**. Is it Really Cost-Effective to Risk-Assess all Hospitalized Patients for Pressure Ulcers Every Nursing Shift? *ISPOR European Congress*; October 31, 2016, Vienna, Austria.
9. **Padula WV**. Is it Really Cost-Effective to Risk-Assess all Hospitalized Patients for Pressure Ulcers Every Nursing Shift? *Society of General Internal Medicine*; April 21, 2017, Washington, DC.
10. **Padula WV**. How Cost-Effective Is It to Risk-Assess all Hospitalized Patients for Pressure Ulcers Every Nursing Shift? *iHEA*; July 12, 2017, Boston, MA.
11. **Padula WV**, Karmarkar T, Gaskin D, Rodriguez C. Cost-effectiveness of Staged Direct-Acting Antiviral Treatment Strategies on an Integrated Healthcare System. *ISPOR International Conference*; May 22, 2018, Baltimore, MD.

#### Workshops

1. Padula WV, McQueen RB, Campbell JD. Cost-effectiveness Modeling in Microsoft Excel. Amgen Global Health Economics; July 2011, Thousand Oaks, CA.
2. Marshall D, Crown W, IJzermann M, **Padula WV**. Simulation Modeling Applications in Healthcare Delivery Research – Emerging Good Practices. *ISPOR International Conference*; June 2, 2014. Montreal, Canada.
3. Marshall D, Crown W, IJzermann M, **Padula WV**. Dynamic Simulation Modeling to Evaluation Complex System Interventions for Health Care Delivery Research – What Methods for What Problems? *ISPOR International Conference*; November 11, 2014, Amsterdam, Netherlands.
4. Nuchols TK, Meltzer DO, **Padula WV**, Doyle B. How to Estimate the Value of QI: The Basics. *Society of Hospital Medicine*; March 22, 2015, Washington, DC.
5. Pasupathy K, **Padula WV**, Morton A, Thokala P. Constrained Optimization: Why Making Pizza and Maximizing Health Care Value are the Same Problem. *ISPOR European Congress*; November 9, 2016, Vienna, Austria.
6. IJzerman M, Tosh J, Thokala P, **Padula WV**. Optimal Allocation of Resources in Managing Medical Device Portfolios. *ISPOR International Conference*; May 23, 2017, Boston, MA.
7. **Padula WV**, Corbin L. Health Economics of a Solid Pressure Ulcer/Injury Program. *AAWC Pressure Ulcer Summit*; February 6, 2019, Atlanta, GA.

8. **Padula WV**, Sculpher M, Vanness DJ, Conti RM. Tailoring Opportunity Costs to State Budgets and Cost-effectiveness Thresholds: How to Broaden the Impact of Value Assessment in the U.S. with State and Commercial Payers. *ISPOR International Conference*; May 18, 2020, Orlando, FL.
9. **Padula WV**, McQueen RB, Conti RM, Tierce J. Understanding Intricacies of Value Assessment: Learning How to Conduct Economic Evaluation of Health Services and What Makes This Approach Different from Health Technology Assessment. *ISPOR International Conference*; May 18, 2020, Orlando, FL.
10. **Padula WV**, Crown W, Adamson B, Vanness D. How to Apply Machine Learning to Health Economics and Outcomes Research: Findings from the ISPOR Machine Learning Task Force. *ISPOR International Conference*; May 16, 2022, Washington, DC.

#### Issue Panels

1. **Padula WV**, Cohen JT, Wrightson T; Moderator: McQueen RB. Controversies in Transparency and Sensitivity Recommendations from The Second Panel on Cost-effectiveness in Health and Medicine. *ISPOR International Conference*; May 24, 2017, Boston, MA.
2. Kahveci R, **Padula WV**, Jolanta Bilinska, Elizabeta Zisovska; Moderator: van Halteren AR. Using Economic Evaluation to Illustrate Value in Health System Quality Improvement. *Health Technology Assessment International (HTAi)*; June 20, 2017, Rome, Italy.
3. Burkom HS, **Padula WV**, Kan H, Kharrazi H, Lee JA; Moderator: Saria S. Machine Learning Methods in the Statistical Prediction of Health Outcomes. *Joint Statistical Meeting (JSM)*; Aug 1, 2017, Baltimore, MD.
4. **Padula WV**, Palumbo F, Kesselheim A; Moderator: Hoffman D. Stuart Rome Lecture, *Panel on Drug Pricing*. Carey School of Law, University of Maryland; March 8, 2018, Baltimore, MD
5. **Padula WV**, Anderson GA, Byron Wornson; Moderator: Karlin-Smith S. Current Legislative, Market & Regulatory Approaches to Drug Accessibility. *Drug Accessibility and Pricing Symposium*, Carey Business School, Johns Hopkins University; March 19, 2018, Baltimore, MD
6. Black JM, **Padula WV**, Santamaria N, Geffen A, Call E. The Science, Clinical Evidence and Health Economics of Pressure Injury Prevention. *Wound Ostomy and Continence Nursing Society Annual Conference*; June 5, 2018, Baltimore, MD.
7. Steuten L, Stuart B, Beaudin-Seiler B, **Padula WV**, Towse A. Go Where The Money Is: Capturing Value Across the Health Care System. *ISPOR European Congress*; November 4, 2019, Copenhagen, Denmark.
8. **Padula WV**, Nuckols T. Implementation Science: Considerations for the 2019 Guideline. *National Pressure Ulcer Advisory Panel (NPUAP) 2019 International Guideline Launch*; November 16, 2019, Los Angeles, CA.
9. **Padula WV**, Marshall D, Ghalchi D, Ghalchi M. The Administrator's Perspective. *National Pressure Ulcer Advisory Panel (NPUAP) 2019 International Guideline Launch*; November 16, 2019, Los Angeles, CA.
10. **Padula WV**, Kim JW, Schlanger SJ, Kochan D. Symposium on the Economics and Law of Pharmaceutical Regulation: Emerging Issues. *Law & Economics Center, George Mason University*; January 28, 2021.
11. Mooney S, **Padula WV**, Shah N, Wilcox A, Waitman R, Mendonco E. Progress, Challenges and Opportunities Toward Implementation of AI and Data Science in Medicine. *Translational Science 2021*; March 31, 2021
12. Rose S, **Padula WV**, Basu A, Denteh A, Kreif N. Health Economics & Algorithms. *Stanford AI + Health Online Conference*; December 8, 2021.

13. Hopkins G, Gulnaz T, Baguneid M, **Padula WV**, DiSanto K, Geraghty J. Improving Patient-related Outcomes through Value-Based Wound Care. *World Union of Wound Healing Societies*; March 2, 2022, Abu Dhabi, UAE.
14. Armstrong DG, **Padula WV**, Nelson J. Complexity Bias in the Prevention of Adverse Events and the Role of Nutrition. *DFCon 2022*; October 1, 2022, Hollywood, CA.
15. Sciarretta K, **Padula WV**, Siddiqui M, Soghoian D, Tandon A, Trahan R. Health-At-Home Summit Panel: How Can Investors and Payers Contribute to Technology Development. Biomedical Advanced Research and Development Authority (BARDA); February 15, 2023, Washington, D.C.

#### Poster Abstracts

1. MacDonell RE, **Padula WV**, Yilmaz T. Triplet Pregnancy: To Reduce or Not to Reduce? Annual Meeting of the *North American Society for Psychosocial Obstetrics and Gynecology*. New Haven, CT 2009.
2. McCollum M, Slejko JF, **Padula WV**. Identifying comorbid depression among adults with diabetes in secondary databases. *American College of Clinical Pharmacy and European Society of Clinical Pharmacy International Congress on Clinical Pharmacy*; April 24–28, 2009, Orlando, FL.
3. **Padula WV**, Mishra MK, Yilmaz T, Weaver CW. Improving the quality of pressure ulcer prevention using statistical process control methods. *International Society for Quality in Healthcare (ISQUA)*; October 2009, Dublin, Ireland.
4. Padula WV, Nelson CA, **Padula WV**, Benabib R, Yilmaz T, Krevisky S. Modifying postural adaptation following a CVA through prismatic shift of visuo-spatial egocenter. *American Academy of Optometry*; November 2009, Orlando, FL.
5. **Padula WV**, Mishra MK, Makic MB, Sullivan PW. A Cost-Effectiveness Analysis for the Prevention of Hospital-Acquired Pressure Ulcers. *Society of Medical Decision Making Annual North American Meeting*; October 2009, Hollywood, CA.
6. Padula WV, Nelson CA, **Padula WV**, Benabib R, Yilmaz T, Krevisky S. Modifying postural adaptation following a CVA through prismatic shift of visuo-spatial egocenter. *National Academy of Practices*; March 2010, Washington, DC.
7. Sills MR, **Padula WV**, Walters N, Anderson H. Epidemiology of the Spring (April-June 2009) H1N1 Surge in 25 Children's Hospital Emergency Departments. *Pediatric Academic Societies*; May 2010, Vancouver, BC.
8. Cordero-Coma M, Yilmaz T, Rodriguez E, **Padula WV**, et al. Use of Control Charts to Monitor Post-Cataract Surgery Acute Endophthalmitis in Spain. Annual Meeting, *The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting*; May 2010, Ft Lauderdale, FL.
9. Gallagher MJ, Yilmaz T, **Padula WV**, Cordero-Coma M, MacDonell RE. To determine the influence of geographic location and insurance status on the likelihood of receiving a diagnosis of cataract. Annual Meeting, *ARVO Annual Meeting*; May 2010, Ft Lauderdale, FL.
10. Sills MR, Hall M, Simon HK, Fieldston ES, Walter N, Levin JE, Brogan TV, Hain PD, Goodman DM, Fritch-Levens DD, Fagbuyi DB, Mundorff MB, Libby AM, Anderson HO, **Padula WV**, Shah SS. Resource burden at children's hospitals experiencing surge volumes during the spring 2009 H1N1 influenza pandemic. *American Public Health Association Annual Meeting*, Denver, November, 2010.
11. **Padula WV**, Nair K. Determining the Cost of Obesity and its Major Comorbidities from a Commercial Claims Database. *ISPOR International Congress*; May 2011, Baltimore, MD.
12. **Padula WV**, Mishra MK, Weaver T, Weaver CD, Splaine ME. Identifying improvement of pressure ulcer prevention at the point of care with multiple methods in the department of surgery. *ISPOR International Congress*; May 2011, Baltimore, MD.

13. Van Vliet M, **Padula WV**, Mishra MK, Kerrigan C. Decision analysis in determining cost effectiveness in abdominal wall reconstruction. *New England Society for Plastic and Reconstructive Surgeons*; June 2011, Cape Cod, MA.
14. **Padula WV**, Cordero-Coma M, Yilmaz T, Campbell JD. A Cost-effectiveness Analysis of Off-label Biologics to Treat Sarcoid Posterior Uveitis Versus Posterior Uveitis Versus Standard of Care: Comparing Infliximab to Methotrexate and Systemic Steroids. *Society of Medical Decision Making North American Meeting*; October 2011, Chicago, IL.
15. **Padula WV**, Makic MBF, Mishra MK, Nair KV, Campbell JD, Wald H, Valuck RJ. An off-the-shelf catalogue of quality improvement interventions to implement in the prevention of pressure ulcers for hospital settings. *ISPOR European Congress*; November 2012, Berlin, Germany.
16. **Padula WV**, Mishra MK, Makic MBF, Nair KV, Campbell JD, Wald H, Valuck RJ. Implementation of Quality Improvement Interventions for Pressure Ulcer Prevention in University HealthSystem Consortium Hospitals. *ISPOR International Congress*; May 2013, New Orleans, LA.
17. **Padula WV**, Makic MBF, Mishra MK, Nair KV, Campbell JD, Wald H, Valuck RJ. Comparative Effectiveness of Quality Improvement Interventions for Pressure Ulcer Prevention in US Academic Hospitals. *Society of Medical Decision Making North American Meeting*; Oct 2013, Baltimore, MD.
18. **Padula WV**, Heru S, Campbell JD. Societal and Policy Implications for Medically Necessary Services and Preventive Care in the U.S. Transgender Population: a cost-effectiveness analysis. *Society of Medical Decision Making North American Meeting*; Oct 2014, Miami, FL.
19. **Padula WV**, Larson RA, Conti RM. What is the Most Cost-effective Strategy for Treating Chronic Myeloid Leukemia after Imatinib Loses Patient Exclusivity in the United States? *Society of Medical Decision Making North American Meeting*; Oct 2014, Miami, FL.
20. **Padula WV**, Worku A, Mishra MK, Meltzer DO. Comparing Evidence-based Decision Tools to Checklists for the Prevention of Hospital-acquired Conditions: a value of information analysis. *Society of Medical Decision Making North American Meeting*; Oct 2014, Miami, FL.
21. **Padula WV**, McElroy L, Holl J. Cost Minimization of After Hours Postoperative Care for Transplant Recipients. *Society of Medical Decision Making North American Meeting*; Oct 2014, Miami, FL.
22. **Padula WV**, Larson RA, Conti RM. What is the Most Cost-effective Strategy for Treating Chronic Myeloid Leukemia after Imatinib Loses Patient Exclusivity in Europe? *ISPOR European Congress*; Nov 2014, Amsterdam, NL.
23. **Padula WV**, Gibbons RD, Pronovost PJ, Hedeker D, Mishra MK, Makic MBF, Bridges JFP, Wald HL, Valuck RJ, Ginensky AJ, Ursitti A, Venable LR, Epstein Z, Meltzer DO. Using Clinical Data to Predict High-cost, Performance Coding Issues Associated with Pressure Ulcers: a multilevel cohort model. *AcademyHealth*; Jun 2016, Boston, MA.
24. **Padula WV**. The Real-world Effectiveness and Value of Sacral Dressings to Prevent Hospital-acquired Pressure Injuries in Academic Medical Centers: An Observational Cohort Study. *Society of Hospital Medicine*; April 28, 2017, Las Vegas, NV.
25. **Padula WV**, Phelps CE, Moran D, Earley C. Allocating Provider Resources to Accurately Diagnose and Treat Restless Leg Syndrome (RLS): A Cost-Utility Analysis. *ISPOR International Conference*; May 24, 2017, Boston, MA.
26. **Padula WV**, Davidson PM, Nagarajan M, Pronovost PJ. Investing in Skilled Specialists to Grow Hospital Infrastructure and Improve Quality. *ISPOR European Congress*; November 6, 2017, Glasgow, UK.
27. **Padula WV**, So Yeon Kang, Farah Yehia, Michael DeStefano. Cost-effectiveness of Continuous Lateral Rotation Therapy Beds in ICU. *NPUAP Annual Meeting*; March 3, 2018, Las Vegas, NV.

28. **Padula WV**, Parasrampur S, Socal M, Anderson GF. Is the Orphan Drug Act Being Used as a Loophole to Extend Periods of Drug Exclusivity? *ISPOR International Conference*; May 22, 2018, Baltimore, MD.
29. **Padula WV**, Chen HY, Phelps CE. Is the Choice of Willingness-to-Pay Threshold in Cost-utility Analysis Endogenous to the Resulting Value of Technology? *ISPOR European Congress*; November 13, 2018, Barcelona, Spain.
30. **Padula WV**, Parasrampur S, Socal M, Anderson GF. How Long Can The Exclusivity Period for Orphan Drugs be Extended? *ISPOR European Congress*; November 14, 2018, Barcelona, Spain.
31. **Padula WV**, Santamaria N, Black JM. Pressure Injury Prevention to Avoid Patient Harm and Costly Penalties: The Standardized Pressure Injury Prevention Protocol (SPIPP). *Society of Hospital Medicine (SHM) Annual Meeting*; March 25, 2019, Washington, DC.
32. **Padula WV**, Kelley M. Development of a machine learning algorithm to predict future risk of patients for high-cost, hospital-acquired pressure injuries. *ISPOR International Conference*; May 20, 2019, New Orleans, LA.
33. Jin S, Amezcua L, Moghavem N, **Padula WV**. A Cost-effectiveness Analysis of Biologic Compared with Chemical Disease Modifying Drugs in Treating Multiple Sclerosis in US. *ISPOR International Conference*; May 16, 2022, Washington, DC.
34. Gu B, **Padula WV**. Cost-effectiveness Analysis of Non-invasive Screening in Patients with Diabetic Foot Ulcers. *ISPOR International Conference*; May 17, 2022, Washington, DC.
35. Davis I, Gong CL, Yieh L, **Padula WV**. Cost-effectiveness of Therapeutic Hypothermia for Neonates with Mild Hypoxic-Ischemic Encephalopathy. *ISPOR International Conference*; May 17, 2022, Washington, DC.
36. Zheng H, Magee GA, Tan TW, Armstrong DG, **Padula WV**. Compression Therapy with Early Endovenous Ablation in Venous Leg Ulceration in the U.S.: A Cost-effectiveness Analysis. *ISPOR International Conference*; May 17, 2022, Washington, DC.

### Invited Seminars and Lectures

#### “Patient Preferences”

- PHRD 7400 Pharmacoeconomics, University of Colorado; Oct 6, 2009, Aurora, CO.
- PHRD 7400 Pharmacoeconomics, University of Colorado; Oct 18, 2010, Aurora, CO.
- PHRD 7400 Pharmacoeconomics, University of Colorado; Oct 8, 2011, Aurora, CO.
- PHRD 7400 Pharmacoeconomics, University of Colorado; Nov 9, 2012, Aurora, CO.
- Summer Program in Outcomes Research Training (SPORT), University of Chicago; July 10, 2014, Chicago, IL.
- Summer Program in Outcomes Research Training (SPORT), University of Chicago; July 14, 2015, Chicago, IL.

#### “Descriptive Statistics”

- PHRD 6400 Biostatistics, University of Colorado; Oct, 2011, Aurora, CO.

#### “Meta-analysis”

- PHRD 6400 Biostatistics, University of Colorado; Nov 14, 2012, Aurora, CO.

#### “U.S. Health Policy and Pharmaceutical Policy”

- PHRD 5450 US Healthcare Systems, University of Colorado; Jan-May, 2011, Aurora, CO.
- PHRD 5450 US Healthcare Systems, University of Colorado; Jan-May, 2012, Aurora, CO.
- PHRD 5450 US Healthcare Systems, University of Colorado; Jan-May, 2013, Aurora, CO.

“Comparative Effectiveness of Quality Improvement Strategies for Pressure Ulcer Prevention at U.S. Academic Medical Centers.”

- *Outcomes Research Workshop*, Biological Sciences Division, University of Chicago; October 17, 2013, Chicago, IL.
- *Chicago LEARN*, UHC; October 22, 2013, Chicago, IL.
- *Nursing Grand Rounds*, University of Chicago; February 17, 2014, Chicago, IL.
- Wound Ostomy and Continence Nurses (WOCN) Society, Rocky Mountain Chapter; August 24, 2014, Denver, CO.
- *WOCN Society*, Rocky Mountain Chapter; October 14, 2014, Salt Lake City, UT.
- *WOCN Society*, Chicago-area Chapter,; November 4, 2014, Chicago, IL
- *Sigma Theta Tau*, Nebraska Chapter; November 18, 2014, Omaha, NE.

“Determining the Cost of Obesity and its Common Comorbidities from a Commercial Claims Database.”

- *Health Economics Workshop*, Harris School of Public Policy, University of Chicago; February 27, 2014, Chicago, IL.

“Best-practices in Quality Improvement to Achieve HAPU Prevention.”

- *VCU Pressure Ulcer Summit*; March 20, 2014, Richmond, VA.
- *VCU Stepping Stones*; September 11, 2015, Richmond, VA.
- *WOCN Southeast*; August 19, 2016

“Cost-effectiveness Analysis and Comparative Effectiveness Research.”

- *National Institute for Minority Health Disparities (NIMHD) Conference*; August 16, 2014, Bethesda, MD.
- *National Institute for Minority Health Disparities (NIMHD) Conference*; August 14, 2015, Bethesda, MD.
- *Health Equity Jam Session*, Hopkins Center to Eliminate Cardiovascular Health Disparities; September 23, 2015, Baltimore, MD.
- JHSPH 300.715.01: Research and Evaluation Methods for Health Policy II. April 12, 2016, Baltimore, MD

“Using EHR data to dynamically predict hospitalized patient Braden Scores”

- *Outcomes Research Workshop*, Biological Sciences Division, University of Chicago; October 8, 2014, Chicago, IL
- *Chicago LEARN*, UHC; October 16, 2014, Chicago, IL

“Pay for Performance”

- *Social Context of Medicine and the American Healthcare System*, Pritzker School of Medicine, University of Chicago; November 4, 2014, Chicago, IL

“Healthcare and Hospitality: Can They Coexist?”

- *Kennedy-King Community College*; February 18, 2015, Chicago, IL

“Best-practices for Dissertations and Theses”

- *ISPOR Western Pharmacoeconomics Conference* (with M. Coca-Perrillon, A. Harrington, M. Mann), Roundtable; March 5, 2015, Denver, CO.

“Quality Improvement Frameworks to Implement Evidence-based Practices for Pressure Ulcer Prevention”

- *National Pressure Ulcer Advisory Panel (NPUAP)*; May 12, 2015, Online Webinar.
- *WOCN Society Annual Meeting*; June 11, 2015, San Antonio, TX.
- *Stepping Stones Conference on Wound Care*, Virginia Commonwealth University; September 11, 2015, Richmond, VA.

- *New Jersey Hospital Association (NJHA)*; June 15, 2016, Online Webinar.
- “Applying Dynamic Simulation Modeling Methods in Health Care Delivery Research – The SIMULATE Checklist and Emerging Good Practices”
  - *ISPOR*; August 25, 2015, Online Webinar.
- “Pressure Ulcer Prevention: New Data for Improved Outcomes”
  - *Symposium on Advanced Wound Care*, Society for Advanced Wound Care (SAWC); September 26, 2015, Las Vegas, NV.
- “Managing Hospital EHR Data to Evaluate and Predict Pressure Ulcer Outcomes”
  - *NPUAP 2016 Staging Consensus Conference*; April 9 2016, Chicago, IL.
- “Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic-Phase After Generic Entry of Imatinib”
  - *Center for Pharmaceutical Outcomes Research (CePOR) Graduate Student Seminar*, University of Colorado; September 8, 2016, Aurora, CO.
- “Building and Presenting Constrained Optimization Models in Healthcare: A Case Study of Optimal Kidney Matching”
  - *Economic Outcomes Research Workshop*, ISPOR European Congress; October 31, 2016, Vienna, AU.
- “Paving the Way to High-value Pressure Injury Care with Big Data”
  - Molnlycke; November 17, 2016, Online Webinar.
  - *2017 Conference, SAWC*; April 12, 2017, San Diego, CA.
  - Molnlycke; June 5, 2017, Chicago, IL.
- “Improving the Quality and Affordability of Pressure Injury Prevention Using Big Data”
  - *Oxford Institute for Nursing, Midwifery and Allied Health (OxINMAHR) Seminar*, Oxford Brookes University; December 1, 2016.
- “Let’s Start at the Top: Getting Administrative Buy-in”
  - *NPUAP Annual Conference*; March 10 2017, New Orleans, LA.
- “Emerging Healthcare Models”
  - *ANCC 2017 Strategic Planning Meeting*; July 12, 2017, Silver Spring, MD.
- “Developing New Policies in Response to Rising Drug Prices in the U.S.”
  - *Oxford University Health Economics Research Center (HERC)*; November 15, 2017, Oxford, UK.
  - *ICON – Oxford Outcomes Group*; November 17, 2017, Oxford, UK.
- “Optimizing Pressure Injury Prevention with an Enhanced Quality Improvement Bundle”
  - *Wound Ostomy Continence Nurses Society, Mid-Atlantic Meeting*; November 1, 2017, Baltimore, MD.
  - *Tissue Viability Nurses Society*, London Chapter; November 15, 2017, London, UK.
- “Deciphering The Codes: ICD 10, ICD 11, LOINC, SNOMED and CMS”
  - *NPUAP Annual Conference*; March 3, 2018, Las Vegas, NV.
- “Integrating Sensor Technology into Pressure Injury Prevention: Care Pathway for Better Outcomes”
  - *American Nurses Association (ANA) Quality & Innovation Conference*, Breakfast Symposium; March 22, 2018, Orlando, FL.

“The Orphan Drug Act: Uses and Abuses”

- *The Research Program Seminar in Pharmaceutical Economics and Policy*, UCLA Fielding School of Public Health; January 10, 2019, Los Angeles, CA.

“Updates on Pressure Injury Prevention Measures and Methods”

- *Centers for Medicare & Medicaid Services (CMS) Quality Conference 2019*; January 30, 2019, Baltimore, MD.
- *CMS HIIN Leadership, Improvement Advisors, and Hospitals Pacing Event*; May 2, 2019, Los Angeles, CA.
- *Healthcare Executive Forum 2019*; May 7, 2019, Houston, TX.
- *European Wound Management Association (EWMA) 2019*; June 3, 2019, Gothenburg, Sweden.
- *Healthcare Association of New York State (HANYS)*; September 4, 2019, New York, NY.
- *National Pressure Ulcer Advisory Panel (NPUAP) World-Wide Pressure Injury Prevention Day*; November 18, 2019, Los Angeles, CA.

“Applications of Machine Learning to Develop a Cost-effectiveness Analysis of Pressure Injury Prevention for Improving Hospital Safety”

- *Centre for Health Economics Seminar*, University of York; July 8, 2019, York, UK.
- *Health Economics and Health Technology Assessment (HEHTA) Seminar*, University of Glasgow; August 6, 2019, Glasgow, UK.

“Ten Lessons to Serve a Growing Purpose of Economic Evaluation: A Tale of Two Countries”

- *Global Health Economics Lunch & Learn*, Amgen; November 19, 2019, Thousand Oaks, CA.
- *Center for Health Services & Outcomes Research (CHSOR) Seminar*, Johns Hopkins Bloomberg School of Public Health; January 14, 2021, Baltimore, MD.
- *Center for the Evaluation of Value and Risk in Health (CEVR)*, Tufts Medicine; March 24, 2021, Boston, MA.



## **ADDITIONAL INFORMATION**

### **Personal Statement**

William Padula, PhD is Assistant Professor of Pharmaceutical & Health Economics in School of Pharmacy at University of Southern California in Los Angeles, CA. He is a Fellow in the Leonard D. Schaeffer Center for Health Policy and Economics. His research explores theoretical foundations at the interface of medical cost-effectiveness analysis, decision-making and data science. He has been particularly prolific pertaining to issues around drug pricing and patient safety in hospitals.

He is a Co-founder and Principal for Stage Analytics, a consulting firm in health economics and outcomes research. He was President & CEO of the U.S. National Pressure Injury Advisory Panel (NPIAP) from 2021-2022, a global independent board and panel that innovates guidelines for pressure injury prevention and treatment. He was also Commissioner for the American Nurses Credentialing Center (ANCC) Magnet® Recognition Program from 2016-2019.

He is the author of over 100 articles and book chapters that have been published in leading medical, economic, bioinformatics and health policy journals. His book about *The Handbook of Applied Economics for Vaccines* has been highly regarded as a teaching textbook in economic evaluation for global health and infectious disease.

He is an Associate Editor of *Value in Health*, and serves on the editorial boards of *Applied Health Economics and Health Policy* and *Journal of Clinical Nursing*. His work has been featured in the *New York Times*, *The Atlantic*, *Forbes* and other media. He is a recipient of PhRMA Foundation's 2023 Frontier Award; the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2021 Bernie J. O'Brien New Investigator Award; the 2019 ISPOR Award for Excellence in Health Economics and Outcomes Research from the; the 2015 AcademyHealth Outstanding Dissertation Award; and the 2014 Society for Advancement in Wound Care (SAWC) Young Investigator Award.

Previously, he was an Assistant Professor in the Department of Health Policy & Management at Johns Hopkins Bloomberg School of Public Health in Baltimore, MD, and has held adjunct appointments at the School of Nursing and The Armstrong Institute for Patient Safety and Quality at Hopkins Medicine. He has been a visiting scholar at University of York, University of Sydney, The Oxford Institute for Nursing, Midwifery and Allied Health (OxINMAHR), and the University of Technology Sydney. Dr. Padula received his B.S. in Chemical Engineering from Northwestern University, M.S. in Evaluative Clinical Science from Dartmouth College, M.Sc. in Data Analytics from University of Chicago, and Ph.D. in Pharmaceutical Economics from University of Colorado.

### **Key Words**

Health Economics; Data Science; Cost-effectiveness Analysis; Economic Evaluation; Machine Learning; Bioinformatics; Health Services Research; Health Outcomes Research; Quality Improvement; Patient Safety